var title_f15_43_16048="Ampullary carcinoma CT";
var content_f15_43_16048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ampullary carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spiral abdominal CT scan showing a small ampullary mass (arrow) in a 74-year-old woman with occult gastrointestinal blood loss. Note that the pancreatic head appears uninvolved.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of A James Moser, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16048=[""].join("\n");
var outline_f15_43_16048=null;
var title_f15_43_16049="Stiripentol: International drug information";
var content_f15_43_16049=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Stiripentol: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4292908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Diacomit (AT, BE, CY, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, NL, NO, PL, PT, SE, SI)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4292909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4292910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory generalized tonic-clonic seizures in conjunction with clobazam and valproic acid in patients with severe myoclonic epilepsy in infancy (Dravet's syndrome) who's seizures are not adequately controlled with clobazam and valproic acid alone",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4292912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;3 years and Adults: In conjunction with clobazam and valproic acid: Initial: Dose should be gradually increased over 3 days to a final dose of 50 mg/kg/day in 2-3 divided doses with food (excluding fruit juice, dairy, or caffeinated or carbonated products)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Clobazam concentrations have increased 2- to 3-fold when given with stiripentol; a clobazam dosage reduction of 25% per week may be required in the presence of clobazam toxicity (drowsiness, hypotonia, and irritability)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4292913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for oral suspension [sachet]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     250 mg [contains 2.5 mg aspartame and 2.4 mg sorbitol; tutti-frutti flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     500 mg [contains 5 mg aspartame and 4.8 mg sorbitol; tutti-frutti flavor]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10526 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16049=[""].join("\n");
var outline_f15_43_16049=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4292908\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4292909\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4292910\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4292912\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821069\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4292913\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10526\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10526|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_43_16050="Pitting edema PI";
var content_f15_43_16050=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pitting edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows how a doctor or nurse can check for swelling in a person's foot. To check for swelling, a doctor or nurse presses down on the skin near the ankle (as shown in Picture A) and then lifts his or her finger up. If the skin stays indented (as shown in Picture B), the person has swelling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bickley LS, Szilagyi PG. Bates' Guide to Physical Examination and History Taking, 9th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16050=[""].join("\n");
var outline_f15_43_16050=null;
var title_f15_43_16051="Patient information: Peritoneal dialysis (The Basics)";
var content_f15_43_16051=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16433\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"         Anatomy of the urinary tract",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/22/25952\">",
"          Peritoneal dialysis",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/46/5859\">",
"         Patient information: Acute kidney failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/42/19107\">",
"         Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/35/28212\">",
"         Patient information: Chronic kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/2/18467\">",
"         Patient information: Dialysis and diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/1/25619\">",
"         Patient information: Hemodialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/33/8722\">",
"         Patient information: Low-potassium diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/19/41266\">",
"         Patient information: Low-sodium diet (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/5/13398\">",
"         Patient information: Chronic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/26/9635\">",
"         Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/41/42640\">",
"         Patient information: Low potassium diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/61/39890\">",
"         Patient information: Low sodium diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/10/14501\">",
"         Patient information: Peritoneal dialysis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Peritoneal dialysis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/peritoneal-dialysis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H14020197\">",
"      <span class=\"h1\">",
"       What is peritoneal dialysis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Peritoneal dialysis is a treatment for kidney failure. Normally, the kidneys work to filter the blood and remove waste and excess salt and water (",
"      <a class=\"graphic graphic_figure graphicRef79864 \" href=\"UTD.htm?26/28/27072\">",
"       figure 1",
"      </a>",
"      ). Kidney failure, also called &ldquo;end-stage renal disease,&rdquo; is when the kidneys stop working completely.",
"     </p>",
"     <p>",
"      Peritoneal dialysis is a procedure that involves piping a special fluid into the belly. This fluid collects waste and excess salt and water from the blood. Then the used fluid drains out of the belly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14020204\">",
"      <span class=\"h1\">",
"       Where will I do peritoneal dialysis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You will do peritoneal dialysis at your home. You will need to do it every day.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14020211\">",
"      <span class=\"h1\">",
"       When will I start peritoneal dialysis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You and your doctor will decide the right time for you to start. It will depend partly on how well your kidneys work, your symptoms, and your overall health. Your doctor will do blood tests to check how well your kidneys are working.",
"     </p>",
"     <p>",
"      Before you start peritoneal dialysis, you need surgery to create a way for the fluid to get in and out of your belly. The doctor will put a thin tube (called a &ldquo;catheter&rdquo;) in your belly. One end of the tube stays in your belly. The other end stays outside your body. It takes about 2 weeks for your body to heal with the tube in it before you can start dialysis.",
"     </p>",
"     <p>",
"      You will also need to learn how to do peritoneal dialysis. A nurse will teach you (or a family member, if he or she will do it) how to set up and use the equipment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14020218\">",
"      <span class=\"h1\">",
"       What happens during peritoneal dialysis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;During peritoneal dialysis, you will hook up your belly tube to the dialysis tubing (",
"      <a class=\"graphic graphic_figure graphicRef71539 \" href=\"UTD.htm?25/22/25952\">",
"       figure 2",
"      </a>",
"      ). You will pipe clean fluid into your belly. The fluid will stay there for a certain amount of time. When the fluid is in your belly, it&rsquo;s called a &ldquo;dwell.&rdquo; During a dwell, your belly might feel full or bloated, but it shouldn&rsquo;t hurt.",
"     </p>",
"     <p>",
"      After the dwell, you will drain the used fluid out of your belly and throw it away. Then you will refill your belly with clean fluid. Each time you drain the used fluid and refill your belly with clean fluid, it&rsquo;s called an &ldquo;exchange.&rdquo; It&rsquo;s important to follow all your doctor&rsquo;s instructions about each exchange and dwell.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14020225\">",
"      <span class=\"h1\">",
"       How often will I do peritoneal dialysis and how long does it take?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your schedule depends on the type of peritoneal dialysis you do. There are 2 types of peritoneal dialysis:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Continuous ambulatory peritoneal dialysis (CAPD) &mdash; CAPD is done all day and night. People do the exchanges themselves. People usually do 3 to 5 exchanges during the day and do a dwell overnight. Each daytime exchange takes about 30 to 40 minutes.",
"       </li>",
"       <li>",
"        Continuous cycling peritoneal dialysis (CCPD) &mdash; For CCPD, a machine does the exchanges. CCPD is usually done overnight.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most people can choose the type of peritoneal dialysis they have. Talk with your doctor about which type of peritoneal dialysis is best for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14020232\">",
"      <span class=\"h1\">",
"       What problems can happen with peritoneal dialysis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Problems that can happen with peritoneal dialysis include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An infection of the skin around the tube &mdash; An infection can cause the skin to become red, painful, or hard. Pus might also drain from the area. Treatment usually includes antibiotic medicines or creams.",
"       </li>",
"       <li>",
"        An infection inside the belly (called &ldquo;peritonitis&rdquo;) &mdash; Peritonitis can cause belly pain, fever, nausea, or diarrhea. It can also cause the used fluid to look cloudy. Treatment usually includes antibiotics that go into the belly with the dialysis fluid.",
"       </li>",
"       <li>",
"        A hernia &mdash; A hernia is when a belly muscle becomes weak. It causes an area of the belly to bulge out. It usually doesn&rsquo;t hurt. A hernia is treated with surgery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Call your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The skin around your tube gets red, painful, or hard, or pus drains from it.",
"       </li>",
"       <li>",
"        You have belly pain, fever, or the used dialysis fluid looks cloudy.",
"       </li>",
"       <li>",
"        A part of your belly bulges out.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14020239\">",
"      <span class=\"h1\">",
"       Is there anything else I should do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, you will need to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Weigh yourself every day &mdash; You need to use your weight to figure out each day&rsquo;s dialysis treatment.",
"       </li>",
"       <li>",
"        Take care of the skin around your tube &mdash; Every 1 to 2 days, wash the area carefully, pat it dry, and put an antibiotic cream on it. Keep the area covered with gauze and tape. Tell your doctor or nurse if you injure the area or if the tube moves out of place.",
"       </li>",
"       <li>",
"        Follow a special diet &mdash; You might need to limit the amount of fluids you drink and eat. You might also need to avoid foods with a lot of sodium, potassium, and phosphorous. These are minerals that can build up in your body if you have kidney problems.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14020246\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=see_link\">",
"       Patient information: Chronic kidney disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/42/19107?source=see_link\">",
"       Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/2/18467?source=see_link\">",
"       Patient information: Dialysis and diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/19/41266?source=see_link\">",
"       Patient information: Low-sodium diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=see_link\">",
"       Patient information: Hemodialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/33/8722?source=see_link\">",
"       Patient information: Low-potassium diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=see_link\">",
"       Patient information: Acute kidney failure (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=see_link\">",
"       Patient information: Peritoneal dialysis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"       Patient information: Chronic kidney disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"       Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"       Patient information: Low sodium diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42640?source=see_link\">",
"       Patient information: Low potassium diet (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?15/43/16051?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16433 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16051=[""].join("\n");
var outline_f15_43_16051=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14020197\">",
"      What is peritoneal dialysis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14020204\">",
"      Where will I do peritoneal dialysis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14020211\">",
"      When will I start peritoneal dialysis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14020218\">",
"      What happens during peritoneal dialysis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14020225\">",
"      How often will I do peritoneal dialysis and how long does it take?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14020232\">",
"      What problems can happen with peritoneal dialysis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14020239\">",
"      Is there anything else I should do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14020246\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16433\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"      Anatomy of the urinary tract",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/22/25952\">",
"       Peritoneal dialysis",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=related_link\">",
"      Patient information: Acute kidney failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/42/19107?source=related_link\">",
"      Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=related_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/2/18467?source=related_link\">",
"      Patient information: Dialysis and diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=related_link\">",
"      Patient information: Hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42640?source=related_link\">",
"      Patient information: Low potassium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/33/8722?source=related_link\">",
"      Patient information: Low-potassium diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/19/41266?source=related_link\">",
"      Patient information: Low-sodium diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_43_16052="Spider anatomy";
var content_f15_43_16052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 591px\">",
"   <div class=\"ttl\">",
"    Basic dorsal and ventral spider anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 571px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16052=[""].join("\n");
var outline_f15_43_16052=null;
var title_f15_43_16053="Deep veins of the upper extremity";
var content_f15_43_16053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Deep veins of the upper extremity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 695px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The deep veins of the upper extremity include the paired ulnar, radial and interosseous veins in the forearm, paired brachial veins of the upper arm, and axillary vein. The axillary vein originates at the lower border of the teres major muscle in continuity with the brachial veins. The basilic and cephalic veins, which are superficial veins, contribute to the axillary vein, though many anatomic variations occur. After passing the outer margin of the first rib, the axillary vein continues as the subclavian vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16053=[""].join("\n");
var outline_f15_43_16053=null;
var title_f15_43_16054="Primary headache associated with sexual activity";
var content_f15_43_16054=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary headache associated with sexual activity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/43/16054/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16054/contributors\">",
"     F Michael Cutrer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/43/16054/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16054/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/43/16054/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16054/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/43/16054/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache associated with sexual activity is one of several relatively uncommon headache syndromes that may occur either as a primary headache or as a headache secondary to potentially malignant processes. Careful evaluation for underlying causes is important for these uncommon types of headache.",
"   </p>",
"   <p>",
"    This topic will review primary headache associated with sexual activity. Other types of uncommon primary headache disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=see_link\">",
"     \"Primary stabbing headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22101?source=see_link\">",
"     \"Primary cough headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44356?source=see_link\">",
"     \"Primary exertional headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5700?source=see_link\">",
"     \"Hypnic headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=see_link\">",
"     \"Thunderclap headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16243?source=see_link\">",
"     \"Nummular headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache associated with sexual activity (also referred to as sexual headache, benign vascular sexual headache, and coital cephalalgia) is of two types, preorgasmic and orgasmic, that have distinct clinical features. Sexual headaches are unpredictable and are not necessarily precipitated with every sexual encounter [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preorgasmic headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preorgasmic headache is a dull, usually bioccipital pressure-like or aching pain that appears during sexual activity and increases with mounting sexual excitement. There is often an awareness of increased contraction in neck and jaw muscles. Preorgasmic headache accounts for less than a third of the benign sexual headaches reported in the literature. In one series of 21 patients, the sexual headaches persisted about 30 minutes on average with a range from 1 to 180 minutes, and the frequency of the headaches was related to that of orgasm [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/1\">",
"     1",
"    </a>",
"    ]. In another series of 51 patients with sexual headache, 11 patients had symptoms consistent with preorgasmic headache (ie, pain started mildly and intensified slowly and gradually with increasing sexual excitement) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/3\">",
"     3",
"    </a>",
"    ]. In these patients, the median duration of severe pain was 30 min (range 10 min to 6 hours), while the median duration of mild pain was one hour [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Orgasmic headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orgasmic headache has a sudden explosive onset followed by severe throbbing head pain that occurs just prior to or at the moment of orgasm. Orgasmic headache may rapidly generalize to involve the entire head.",
"   </p>",
"   <p>",
"    Of the two types of sexual headache, orgasmic headache is more common and the only one associated with stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/1,2,4,5\">",
"     1,2,4,5",
"    </a>",
"    ]. In addition, orgasmic headache is particularly worrisome because of its similarity to the headache of subarachnoid hemorrhage (SAH), and because four to 12 percent of patients presenting with SAH due to an aneurysmal rupture cite sexual intercourse as the precipitating event [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Thus, it is mandatory to exclude intracranial bleed and arterial dissection at the first presentation of orgasmic headache.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact prevalence and incidence of primary sexual headache is unknown, but one Danish population-based study found that the lifetime prevalence of sexual headache was 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a case series from Germany of 51 patients with sexual headache, the mean age at onset was 35 years, and the male female ratio was 2.9:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/3\">",
"     3",
"    </a>",
"    ]. Comorbid migraine, benign exertional, and tension-type headache was present in 25, 29, and 45 percent, respectively, of patients with sexual headache.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual headaches may represent a benign primary disorder. However, they may also be a symptom of an underlying potentially malignant pathological process. The differential diagnosis for sexual headache includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Subarachnoid hemorrhage due to aneurysmal rupture or arteriovenous malformation hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Encephalitis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hemorrhage into a cerebral tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pheochromocytoma [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nonhemorrhagic stroke",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Segmental arterial narrowing has been reported in sexual headache [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], suggesting that some sexual headaches may represent one of the reversible cerebral vasoconstriction syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=see_link&amp;anchor=H13#H13\">",
"     \"Thunderclap headache\", section on 'Reversible cerebral vasoconstriction syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spontaneous low cerebrospinal fluid pressure headache is another pressure-like positional type of headache that may arise during sexual activity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache\", section on 'Cause of low CSF pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because myocardial ischemia may occur during sexual intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/15\">",
"     15",
"    </a>",
"    ], referred anginal pain should be considered as a potential cause of sexual headache in individuals with coronary risk factors. Several drugs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/16\">",
"     16",
"    </a>",
"    ], cannabis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/17\">",
"     17",
"    </a>",
"    ], oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/10\">",
"     10",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/1\">",
"     1",
"    </a>",
"    ], have been linked to sexual headaches in case reports. In addition, a number of non-neurologic disorders have been suggested as possible causes for sexual headache. These include sinusitis, glaucoma, hypoglycemia, myxedema, anemia, chronic obstructive pulmonary disease, Cushing's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/18\">",
"     18",
"    </a>",
"    ], and occlusion of the abdominal aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Benign sexual headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;A benign sexual headache syndrome is likely if no abnormality is identified despite a thorough evaluation for structural, vascular, or pharmacologic causes.",
"   </p>",
"   <p>",
"    The occasional occurrence of transient neurologic symptoms such as numbness or paresthesias with sexual headaches has caused some authors to suggest that benign sexual headache should be considered a variant of migraine caused by hemodynamic shifts during orgasm [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/2,10,11\">",
"     2,10,11",
"    </a>",
"    ]. Although many of the patients in reported case series of sexual headache also have a history of migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/4\">",
"     4",
"    </a>",
"    ], the high prevalence of migraine might result in co-occurrence of the two disorders. Therefore, the attribution of sexual headache to migraine without rigorous investigation of potential underlying causes is probably unwise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of benign sexual headache is unknown and the proposed pathophysiological mechanisms are largely speculative. Benign sexual headaches are difficult to study because of their relative rarity and variable clinical presentation. One investigator proposed that preorgasmic headaches arise from excessive contraction of neck and jaw muscles during sexual activity and that they might be avoided by conscious relaxation of these muscles during intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/1\">",
"     1",
"    </a>",
"    ]. Orgasmic headaches have been attributed to rapid increases in blood pressure and heart rate that occur during orgasm [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike benign sexual headache, the headache related to subarachnoid hemorrhage is associated with neck stiffness, focal neurologic symptoms, loss of consciousness, and is in general more protracted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/5\">",
"     5",
"    </a>",
"    ]. Despite the existence of these potentially discriminative factors, the diagnosis of primary headache associated with sexual activity requires that structural causes be excluded.",
"   </p>",
"   <p>",
"    Excluding a structural cause is especially important when the headaches are of the orgasmic type; it is mandatory to exclude intracranial bleed and arterial dissection at the first presentation of orgasmic headache.",
"   </p>",
"   <p>",
"    The work-up typically includes a head CT and lumbar puncture if the patient is within hours of headache onset, or brain MRI with gadolinium and MRA (sometimes with lumbar puncture) if days or weeks have elapsed since onset. The diagnosis of subarachnoid hemorrhage is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link&amp;anchor=H26#H26\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation for pheochromocytoma is warranted when symptoms such as prominent flushing, tachycardia, and sweating are present, particularly if these symptoms are present remote from sexual activity. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once underlying pathology has been excluded, treatment of benign sexual headache should be offered. Preventive medical therapies reported to be effective in case series include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    (25 to 225 mg per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/20-22\">",
"     20-22",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    (40 to 240",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and other beta-blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/18,21-23\">",
"     18,21-23",
"    </a>",
"    ], various triptans [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/21,24\">",
"     21,24",
"    </a>",
"    ], and the combination drug belladonna-phenobarbital-ergotamine tartrate (Bellergal) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a small case series of patients with orgasmic headache, acute triptan treatment was beneficial in about one-half [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one case series, the advice to engage in sexual intercourse more frequently but less strenuously resulted in an apparent reduction in headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following recommendations regarding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    and triptan therapy for sexual headache apply only after a neurovascular lesion has been excluded by an appropriate evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Preventive treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with benign sexual headache that occurs predictably, we suggest preventive treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    starting at 25 mg, taken 30 to 60 minutes before sexual activity. The indomethacin dose can be increased up to 150 mg until a favorable response is obtained. For patients refractory to or intolerant of indomethacin, or for those with comorbid migraine headache, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    starting at 40 mg daily and increasing to 200 mg daily as required.",
"   </p>",
"   <p>",
"    For patients refractory to or intolerant of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , we suggest preventive treatment with a triptan:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The available triptans include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"       zolmitriptan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/9/6293?source=see_link\">",
"       naratriptan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/14/29925?source=see_link\">",
"       rizatriptan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/26/20901?source=see_link\">",
"       almotriptan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/29/42452?source=see_link\">",
"       eletriptan",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/55/9077?source=see_link\">",
"       frovatriptan",
"      </a>",
"      . The choice among these agents should be individualized; different pharmacologic properties and delivery routes may help guide the selection. Sumatriptan can be given as a subcutaneous injection, as a nasal spray, or orally. Zolmitriptan is also available for both nasal and oral use. The others are available for oral use only.",
"     </li>",
"     <li>",
"      We prefer subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      or nasal spray triptan formulations (sumatriptan or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"       zolmitriptan",
"      </a>",
"      ) given 30 to 60 minutes before sexual activity if intercourse is spontaneous or intermittent. For intercourse that will begin in two to four hours,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/26/20901?source=see_link\">",
"       almotriptan",
"      </a>",
"      , sumatriptan,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/14/29925?source=see_link\">",
"       rizatriptan",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/29/42452?source=see_link\">",
"       eletriptan",
"      </a>",
"      are preferred oral agents. For intercourse that will begin in more than four hours, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/55/9077?source=see_link\">",
"       frovatriptan",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/9/6293?source=see_link\">",
"       naratriptan",
"      </a>",
"      are preferred because of their long half-life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For acute treatment of benign sexual headache, we suggest triptan treatment. We prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    intranasal spray 5 mg or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"     zolmitriptan",
"    </a>",
"    intranasal spray 5 mg for acute therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for primary sexual headache is generally quite good, even for those cases associated with transient neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/1,11,22\">",
"     1,11,22",
"    </a>",
"    ]. One of the larger case series that addressed prognosis included 60 patients with headache associated with sexual activity; these were followed for an average of 36 months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/22\">",
"     22",
"    </a>",
"    ]. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At baseline examination, single attacks or single bouts of sexual headache were reported by 45 patients (75 percent), while a chronic course with ongoing headache was reported by 15 (25 percent)",
"     </li>",
"     <li>",
"      Among patients with chronic course of sexual headache at baseline, the remission rate at three years was 69 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Persistent neurologic deficits following sexual headaches have been rarely reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16054/abstract/17\">",
"     17",
"    </a>",
"    ]; any persistent deficit requires investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are two types of headache associated with sexual activity that have distinct clinical features:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Preorgasmic headache",
"      </strong>",
"      is a dull, usually bioccipital pressure-like or aching pain that appears during sexual activity and increases with mounting sexual excitement.",
"     </li>",
"     <li>",
"      <strong>",
"       Orgasmic headache",
"      </strong>",
"      has a sudden explosive onset followed by severe throbbing head pain that occurs just prior to or at the moment of orgasm. Orgasmic headache may rapidly generalize to involve the entire head. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sexual headache may represent a benign primary disorder. However, it may also be a symptom of an underlying potentially malignant pathological process. A benign syndrome is likely if no abnormality is identified despite a thorough evaluation for structural, vascular, or pharmacologic causes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with new-onset or never-evaluated",
"      <strong>",
"       orgasmic",
"      </strong>",
"      headache, we recommend brain imaging with CT or MRI to exclude intracranial hemorrhage, and neurovascular imaging to exclude cervical and intracranial arterial dissection. For patients with new-onset or never-evaluated",
"      <strong>",
"       preorgasmic",
"      </strong>",
"      headache, we suggest neuroimaging to exclude a structural brain lesion. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once underlying pathology has been excluded, treatment of benign sexual headache should be offered. In particular, a neurovascular lesion should be excluded before starting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      or triptan therapy for sexual headache. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with predictable benign sexual headache, we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      (25 to 150 mg taken 30 to 60 minutes before sexual activity) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients refractory to or intolerant of indomethacin, or those with comorbid migraine headache, we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      starting at 40 mg daily. For patients refractory to or intolerant of indomethacin and propranolol, we suggest preventive treatment with a triptan. Another alternative is the combination drug belladonna-phenobarbital-ergotamine tartrate (Bellergal). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Preventive treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For acute therapy of benign sexual headache of the orgasmic type, we suggest triptan treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Preferred agents are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      intranasal spray 5 mg or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"       zolmitriptan",
"      </a>",
"      intranasal spray 5 mg. Empiric evidence suggests the response rate of acute orgasmic headache to triptans is about 50 percent. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Acute treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/1\">",
"      Lance JW. Headaches related to sexual activity. J Neurol Neurosurg Psychiatry 1976; 39:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/2\">",
"      Johns DR. Benign sexual headache within a family. Arch Neurol 1986; 43:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/3\">",
"      Frese A, Eikermann A, Frese K, et al. Headache associated with sexual activity: demography, clinical features, and comorbidity. Neurology 2003; 61:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/4\">",
"      Pascual J, Iglesias F, Oterino A, et al. Cough, exertional, and sexual headaches: an analysis of 72 benign and symptomatic cases. Neurology 1996; 46:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/5\">",
"      Silbert PL, Edis RH, Stewart-Wynne EG, Gubbay SS. Benign vascular sexual headache and exertional headache: interrelationships and long term prognosis. J Neurol Neurosurg Psychiatry 1991; 54:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/6\">",
"      Lundberg PO, Osterman PO. The benign and malignant forms of orgasmic cephalgia. Headache 1974; 14:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/7\">",
"      Locksley HB. Natural history of subarachnoid hemorrhage, intracranial aneurysms and arteriovenous malformations. Based on 6368 cases in the cooperative study. J Neurosurg 1966; 25:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/8\">",
"      Rasmussen BK, Olesen J. Symptomatic and nonsymptomatic headaches in a general population. Neurology 1992; 42:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/9\">",
"      Malignant coital headache. Headache 2002; 42:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/10\">",
"      Porter M, Jankovic J. Benign coital cephalalgia. Differential diagnosis and treatment. Arch Neurol 1981; 38:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/11\">",
"      Martinez JM, Roig C, Arboix A. Complicated coital cephalalgia. Three cases with benign evolution. Cephalalgia 1988; 8:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/12\">",
"      Kapoor R, Kendall BE, Harrison MJ. Persistent segmental cerebral artery constrictions in coital cephalgia. J Neurol Neurosurg Psychiatry 1990; 53:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/13\">",
"      Valen&ccedil;a MM, Valen&ccedil;a LP, Bordini CA, et al. Cerebral vasospasm and headache during sexual intercourse and masturbatory orgasms. Headache 2004; 44:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/14\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/15\">",
"      Servoss SJ, Januzzi JL, Muller JE. Triggers of acute coronary syndromes. Prog Cardiovasc Dis 2002; 44:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/16\">",
"      Biran I, Steiner I. Coital headaches induced by amiodarone. Neurology 2002; 58:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/17\">",
"      Alvaro LC, Iriondo I, Villaverde FJ. Sexual headache and stroke in a heavy cannabis smoker. Headache 2002; 42:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/18\">",
"      Sands GH, Newman L, Lipton R. Cough, exertional, and other miscellaneous headaches. Med Clin North Am 1991; 75:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/19\">",
"      Staunton HP, Moore J. Coital cephalgia and ischaemic muscular work of the lower limbs. J Neurol Neurosurg Psychiatry 1978; 41:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/20\">",
"      Raskin NH. Short-lived head pains. Neurol Clin 1997; 15:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/21\">",
"      Frese A, Gantenbein A, Marziniak M, et al. Triptans in orgasmic headache. Cephalalgia 2006; 26:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/22\">",
"      Frese A, Rahmann A, Gregor N, et al. Headache associated with sexual activity: prognosis and treatment options. Cephalalgia 2007; 27:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/23\">",
"      Paulson GW, Klawans HL Jr. Benign orgasmic cephalgia. Headache 1974; 13:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16054/abstract/24\">",
"      Evans RW, Pascual J. Expert opinion: orgasmic headaches: clinical features, diagnosis, and management. Headache 2000; 40:491.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3362 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C0D21FD3A5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16054=[""].join("\n");
var outline_f15_43_16054=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preorgasmic headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Orgasmic headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Benign sexual headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Preventive treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5700?source=related_link\">",
"      Hypnic headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16243?source=related_link\">",
"      Nummular headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22101?source=related_link\">",
"      Primary cough headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44356?source=related_link\">",
"      Primary exertional headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=related_link\">",
"      Primary stabbing headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=related_link\">",
"      Thunderclap headache",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_43_16055="Stress urinary incontinence in women: Choosing a type of midurethral sling";
var content_f15_43_16055=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stress urinary incontinence in women: Choosing a type of midurethral sling",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/43/16055/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16055/contributors\">",
"     J Eric Jelovsek, MD, MMEd, FACOG, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16055/contributors\">",
"     Jhansi Reddy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/43/16055/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16055/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/43/16055/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16055/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/43/16055/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2822614\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress urinary incontinence (SUI) affects 4 to 35 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. SUI occurs when an increase in intraabdominal pressure exceeds urethral closure pressure, resulting in the involuntary leakage of urine. This may occur with exertion, sneezing, or coughing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of SUI includes both conservative (eg, vaginal pessaries, pelvic floor muscle exercises) and surgical options. Minimally invasive midurethral synthetic slings have become the procedure of choice for many women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/4\">",
"     4",
"    </a>",
"    ]. The first of these was the tension-free vaginal tape, introduced in 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/5\">",
"     5",
"    </a>",
"    ]. The second major procedure, the transobturator midurethral sling, was introduced in 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/6\">",
"     6",
"    </a>",
"    ]. The transobturator procedures are designed to avoid some of the complications of retropubic insertion (eg, bladder perforation, vascular injury, bowel injury). Since that time, many other devices have been developed, with a variety of introducer mechanisms or mesh types [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The process of choosing a type of midurethral sling for women with SUI who have not had a prior anti-incontinence surgery will be reviewed here. Choosing between midurethral slings and other procedures, nonsurgical management of SUI, treatment of recurrent SUI, and diagnosis and treatment of other types of urinary incontinence are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44409?source=see_link\">",
"     \"Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2823335\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several types of sling procedures for treatment of SUI in women. These procedures vary by the location of the sling and by the sling material. Collectively, these slings are referred to as suburethral slings, which is a sling that is inserted through a small vaginal incision and attached to another structure in the pelvis for the purpose of supporting the urethra. Suburethral slings may be either bladder neck or midurethral slings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Midurethral sling &ndash; A suburethral sling that is placed at the level of the midurethra in a tension-free manner. These slings are made of synthetic mesh.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Retropubic midurethral slings",
"      </strong>",
"      (eg, tension-free vaginal tape [TVT]) are inserted through the retropubic space and exit through the abdominal wall in the suprapubic area (",
"      <a class=\"graphic graphic_figure graphicRef59114 \" href=\"UTD.htm?31/0/31744\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Transobturator midurethral slings",
"      </strong>",
"      (eg, TVT Obturator) are inserted through the two obturator foramens and exit through the skin of the groin area (",
"      <a class=\"graphic graphic_figure graphicRef52240 \" href=\"UTD.htm?31/43/32432\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Single incision midurethral slings",
"      </strong>",
"      (eg, MiniArc) (also referred to as mini-slings or mini-tapes) differ from full-length retropubic and transobturator slings in two ways: they are shorter (approximately 8 cm rather than 40 cm) and they require only a vaginal incision, and not an abdominal incision. Different types of these slings may be placed in a retropubic (anchored to the urogenital diaphragm) or transobturator fashion (anchored to the obturator internus muscle).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bladder neck sling &ndash; A suburethral sling that is placed at the level of the proximal urethra and bladder neck (",
"      <a class=\"graphic graphic_figure graphicRef76965 \" href=\"UTD.htm?15/42/16034\">",
"       figure 3",
"      </a>",
"      ). This procedure is usually performed using both vaginal and abdominal incisions. These slings can be made of either biologic materials (including the patient's own tissue) or synthetic mesh.",
"      <br/>",
"      <br/>",
"      Bladder neck slings are also referred to as proximal urethral slings. Alternatively, they are referred to as pubovaginal slings when the arms of the sling material are affixed to the anterior rectus fascia rather than the pubic bone or Cooper's ligament [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H497779\">",
"    <span class=\"h1\">",
"     FULL LENGTH SLINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2822326\">",
"    <span class=\"h2\">",
"     Transobturator versus retropubic midurethral slings",
"    </span>",
"    &nbsp;&mdash;&nbsp;When midurethral sling surgery is planned, the decision must be made whether to use one of two routes: transobturator or retropubic. Retropubic slings were the first midurethral slings introduced, but transobturator slings are now also in widespread use.",
"   </p>",
"   <p>",
"    Transobturator and retropubic slings appear to have comparable efficacy, based upon a meta-analysis of 17 randomized trials and two subsequent randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]. In the meta-analysis, subjective cure rates were the same for transobturator and retropubic approaches (73 and 73 percent, RR 1.0, 95% CI 1.0 to 1.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the two procedures have not been proven to be equivalent. The Trial of Midurethral Slings (TOMUS), the largest randomized trial regarding this issue to-date, which evaluated 597 women who underwent either a transobturator or retropubic sling procedure, found no significant difference in subjective success rates (56 versus 62 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/9\">",
"     9",
"    </a>",
"    ]. Of note, though, it was uncertain whether the two procedures could be considered equally effective, since the difference exceeded the trial's criterion for equivalence (&plusmn;12 percentage points). In contrast, the objective success rates (81 versus 78 percent) were not significantly different and",
"    <strong>",
"     did",
"    </strong>",
"    meet the criteria to consider the two procedures equally effective. At three-year follow-up, women who underwent a transobturator sling procedure were significantly more likely to require additional corrective surgery compared with a retropubic approach (20 versus 1.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some data suggest that the retropubic approach is more effective for women with intrinsic sphincter deficiency (ISD) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Currently, there are no randomized trials comparing the two approaches in women with ISD and further study is needed to determine their efficacy with respect to certain urodynamic parameters. Furthermore, additional study is also needed regarding whether there is any difference between the two approaches when treating women with mixed incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the meta-analysis and the TOMUS trial reported lower rates of urinary tract injury, voiding dysfunction, and blood loss with a transobturator route [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/7,9,16\">",
"     7,9,16",
"    </a>",
"    ]. In the meta-analysis, the transobturator approach resulted in significantly fewer bladder or urethral perforations (1 versus 6 percent; as noted in the preceding section, these were mainly bladder perforations [urethral perforations are rare]) and less voiding dysfunction (4 versus 7 percent). Blood loss was also statistically significantly reduced with the transobturator approach, but the average difference in blood loss (4 mL) is unlikely to be clinically significant.",
"   </p>",
"   <p>",
"    In the meta-analysis, postoperative de novo urinary urgency or urge incontinence occurred at similar rates for both approaches (6 percent each) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/7\">",
"     7",
"    </a>",
"    ]. On the other hand, postoperative groin pain was significantly more likely to occur with a transobturator approach than suprapubic pain with a retropubic approach (12 versus 2 percent); this analysis compared the most likely site of pain based on the anatomy of each approach. Postoperative groin pain typically resolves with the first several postoperative days or weeks, but may persist in some women (in one trial, it continued for two or more weeks in 14 of 21 patients with groin pain among the 132 who had a transobturator procedure) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/17\">",
"     17",
"    </a>",
"    ]. One retrospective cohort study of 53 women reported a higher rate of de novo dyspareunia in women who underwent a transobturator compared with retropubic approach (4 of 17 versus 0) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/18\">",
"     18",
"    </a>",
"    ]; further study is needed to validate these findings.",
"   </p>",
"   <p>",
"    Women with prior abdominal or pelvic surgery or who have an abdominal or inguinal hernia appear to have an increased risk of bowel injury during retropubic sling placement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33562?source=see_link&amp;anchor=H3907444#H3907444\">",
"     \"Stress urinary incontinence in women: Retropubic midurethral slings\", section on 'Bowel injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is controversial whether the transobturator and retropubic approaches have different effects on sexual function (eg, dyspareunia) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/18,24-26\">",
"     18,24-26",
"    </a>",
"    ]. Further study is needed to evaluate this issue.",
"   </p>",
"   <p>",
"    Given these data, we suggest a transobturator rather than a retropubic approach for women who are undergoing midurethral sling surgery for SUI. The most important outcome is the efficacy of the procedure, which appears to be comparable. Thus, the rationale for choosing the transobturator over retropubic approach is based upon the clinical significance of the perioperative complications for each approach. The most important of these is postoperative voiding dysfunction, which occurred less frequently following a transobturator procedure, since women with this complication require bladder catheterization and may need to undergo a procedure to release the sling. Another advantage of the transobturator approach is the decreased risk of bladder perforation. Although this complication is easily managed, it is best to avoid it if possible. The most important potential disadvantage of the transobturator approach is groin pain. A retropubic approach is a reasonable alternative for surgeons who are more familiar with this procedure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    women who are willing to accept a higher risk of complications if there is a potential for higher efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H497696\">",
"    <span class=\"h2\">",
"     Choosing a type of retropubic sling",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two main variations of full-length retropubic midurethral sling, based upon the initial incision site and direction of insertion: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bottom-to-top &ndash; Two needle trocars are inserted through a vaginal incision and passed through the retropubic space, exiting at the abdominal wall (eg, the original TVT device).",
"     </li>",
"     <li>",
"      Top-to-bottom &ndash; Two needle trocars are inserted through abdominal incisions and passed through the retropubic space, exiting through a vaginal incision (eg, SPARC).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice between these two variations of retropubic slings is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33562?source=see_link&amp;anchor=H2819431#H2819431\">",
"     \"Stress urinary incontinence in women: Retropubic midurethral slings\", section on 'Choosing a type of retropubic sling'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H497704\">",
"    <span class=\"h2\">",
"     Choosing a type of transobturator sling",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two variations of transobturator midurethral sling procedures, which vary by direction of trocar insertion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inside-out &ndash; The trocars are passed from a midurethral vaginal incision to exit through bilateral groin incisions (TVT Obturator).",
"     </li>",
"     <li>",
"      Outside-in &ndash; The trocars are passed from bilateral groin incisions to exit through a midurethral vaginal incision (Monarc, TOT).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice between these two variations of transobturator slings is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33401?source=see_link&amp;anchor=H1196365#H1196365\">",
"     \"Stress urinary incontinence in women: Transobturator midurethral slings\", section on 'Choosing a type of transobturator sling'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2823271\">",
"    <span class=\"h1\">",
"     SINGLE INCISION SLINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H497737\">",
"    <span class=\"h2\">",
"     Single incision versus full-length slings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single incision slings (eg, MiniArc) are the newest type of midurethral sling. The purported advantages of single incision slings are less tissue disruption, less risk of visceral injury, and fewer patients requiring catheter use postoperatively than retropubic or transobturator approaches. The success of these goals has not yet been established.",
"   </p>",
"   <p>",
"    There are two variations of single incision slings, based upon their anatomic path and the site to which they are attached:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      U-shaped (U) position into the connective tissue of the urogenital diaphragm",
"     </li>",
"     <li>",
"      Hammock (H) position into the obturator internus muscle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Single incision slings are a relatively new approach. Most studies report an SUI cure rate at 6 to 12 months of 74 to 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/27-32\">",
"     27-32",
"    </a>",
"    ]. There are few long-term data. The only study (n = 60) with two or more years of follow-up does not appear to be representative, reporting a success rate of 16 percent at one year and 10 percent at two years for the Minitape device [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available data are insufficient to guide clinical decisions regarding whether to use a single incision or a full-length sling. Studies have inconsistent results and have compared different types of slings. Two randomized trials comparing TVT SECUR (this device has been removed from the market) using a hammock approach with transobturator full-length slings (TVT Obturator) reached different conclusions. At one-year follow-up, one trial found that objective cure rates were significantly lower for the single incision sling (84 versus 98 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/34\">",
"     34",
"    </a>",
"    ], while the other found comparable rates (84 versus 82 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial comparing TVT SECUR with a retropubic sling (TVT) found comparable resolution of SUI symptoms at one-year follow-up (81 verus 86 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/36\">",
"     36",
"    </a>",
"    ]. However, postoperative incontinence severity was significantly higher in the TVT SECUR group. Another randomized trial comparing a different type of single incision (MiniArc [a hammock position sling]) with a retropubic full-length sling (TVT) found a lower subjective cure rate for the single incision sling at six-month follow-up (59 versus 96 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/37\">",
"     37",
"    </a>",
"    ]. All studies found no difference in significant complication rates between single incision and full-length slings.",
"   </p>",
"   <p>",
"    Two types of single incision variations were evaluated in a randomized trial (n = 285) that compared the u-shaped and hammock positions for the TVT SECUR sling [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/28\">",
"     28",
"    </a>",
"    ]. Subjective cure rates were similar for the two approaches (U: 77 versus H: 76 percent); objective cure rates differed to a greater extent, but did not reach statistical significance (U: 88 versus H: 80 percent). Complication rates were similar for the two groups. Patient satisfaction rates were high for both groups, but were significantly higher in the u-shaped group (U: 86 percent versus H: 78 percent). Thus, this study gives some support to choosing a u-shaped over a hammock position procedure, but further study is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2823278\">",
"    <span class=\"h2\">",
"     Adjustable slings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjustable midurethral slings (eg, Remeex, Ajust) are single incision slings which allow postoperative adjustment of sling tension and are a new development. There are no comparative data regarding these slings [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16055/abstract/38\">",
"     38",
"    </a>",
"    ]. An adjustable sling, Remeex, was evaluated in a population of 38 patients with valsalva leak point pressures &lt;60 cm H20 or maximal urethral closure pressures less than 20 cm H2O. Patients had these slings adjusted according to their symptoms and, at the end of the study, all patients were reported to be asymptomatic for SUI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/8/22658?source=see_link\">",
"       \"Patient information: Urinary incontinence (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/56/35714?source=see_link\">",
"       \"Patient information: Surgery to treat stress urinary incontinence in women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=see_link\">",
"       \"Patient information: Urinary incontinence treatments for women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2822622\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stress urinary incontinence (SUI) is the involuntary leakage of urine on effort or exertion, or on sneezing or coughing. For many women, midurethral sling placement is the procedure of choice. (See",
"      <a class=\"local\" href=\"#H2822614\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transobturator and retropubic midurethral slings appear to have comparable efficacy. Bladder perforation and voiding dysfunction are more likely to occur in women who have undergone a retropubic sling procedure, while groin pain is associated almost exclusively with transobturator slings. (See",
"      <a class=\"local\" href=\"#H2822326\">",
"       'Transobturator versus retropubic midurethral slings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women undergoing full length midurethral sling placement, we suggest a transobturator rather than a retropubic approach (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A retropubic approach is a reasonable alternative for surgeons who are more familiar with this procedure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      certain subgroups of women who are willing to accept a higher risk of complications if there is a potential for higher procedure efficacy, such as in intrinsic sphincter deficiency (ISD). (See",
"      <a class=\"local\" href=\"#H2822326\">",
"       'Transobturator versus retropubic midurethral slings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Single incision midurethral slings are a relatively new development. There are insufficient data to make a recommendation whether surgeons should use either a full-length or single incision sling. For women who undergo a single incision sling procedure, preliminary data suggest that patient satisfaction is higher with the u-shaped rather than hammock position. (See",
"      <a class=\"local\" href=\"#H497737\">",
"       'Single incision versus full-length slings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adjustable midurethral slings (eg, Remeex, Ajust) are single incision slings which allow postoperative adjustment of sling tension and are a new development. These slings require further evaluation. (See",
"      <a class=\"local\" href=\"#H2823278\">",
"       'Adjustable slings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/1\">",
"      Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/2\">",
"      Luber KM. The definition, prevalence, and risk factors for stress urinary incontinence. Rev Urol 2004; 6 Suppl 3:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/3\">",
"      Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/4\">",
"      Jonsson Funk M, Levin PJ, Wu JM. Trends in the surgical management of stress urinary incontinence. Obstet Gynecol 2012; 119:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/5\">",
"      Ulmsten U, Henriksson L, Johnson P, Varhos G. An ambulatory surgical procedure under local anesthesia for treatment of female urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1996; 7:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/6\">",
"      Delorme E. [Transobturator urethral suspension: mini-invasive procedure in the treatment of stress urinary incontinence in women]. Prog Urol 2001; 11:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/7\">",
"      Ogah J, Cody JD, Rogerson L. Minimally invasive synthetic suburethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev 2009; :CD006375.",
"     </a>",
"    </li>",
"    <li>",
"     Walters, MD, Karram, MM. Sling procedures for stress urinary incontinence. In: Urogynecology and Reconstructive Pelvic Surgery, 3rd ed, Mosby Elsevier, Philadelphia 2007. p. 197.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/9\">",
"      Richter HE, Albo ME, Zyczynski HM, et al. Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med 2010; 362:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/10\">",
"      Barber MD, Kleeman S, Karram MM, et al. Transobturator tape compared with tension-free vaginal tape for the treatment of stress urinary incontinence: a randomized controlled trial. Obstet Gynecol 2008; 111:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/11\">",
"      Schierlitz L, Dwyer PL, Rosamilia A, et al. Three-year follow-up of tension-free vaginal tape compared with transobturator tape in women with stress urinary incontinence and intrinsic sphincter deficiency. Obstet Gynecol 2012; 119:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/12\">",
"      O'Connor RC, Nanigian DK, Lyon MB, et al. Early outcomes of mid-urethral slings for female stress urinary incontinence stratified by valsalva leak point pressure. Neurourol Urodyn 2006; 25:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/13\">",
"      Miller JJ, Botros SM, Akl MN, et al. Is transobturator tape as effective as tension-free vaginal tape in patients with borderline maximum urethral closure pressure? Am J Obstet Gynecol 2006; 195:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/14\">",
"      Houwert RM, Venema PL, Aquarius AE, et al. Risk factors for failure of retropubic and transobturator midurethral slings. Am J Obstet Gynecol 2009; 201:202.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/15\">",
"      Gamble TL, Botros SM, Beaumont JL, et al. Predictors of persistent detrusor overactivity after transvaginal sling procedures. Am J Obstet Gynecol 2008; 199:696.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/16\">",
"      Brubaker L, Norton PA, Albo ME, et al. Adverse events over two years after retropubic or transobturator midurethral sling surgery: findings from the Trial of Midurethral Slings (TOMUS) study. Am J Obstet Gynecol 2011; 205:498.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/17\">",
"      Laurikainen E, Valpas A, Kivel&auml; A, et al. Retropubic compared with transobturator tape placement in treatment of urinary incontinence: a randomized controlled trial. Obstet Gynecol 2007; 109:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/18\">",
"      Cholhan HJ, Hutchings TB, Rooney KE. Dyspareunia associated with paraurethral banding in the transobturator sling. Am J Obstet Gynecol 2010; 202:481.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/19\">",
"      Gurshumov EL, Klapper AS, Sierecki AR. Small bowel perforation in a hernia sac after TVT placement at the time of colpocleisis. Int Urogynecol J 2010; 21:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/20\">",
"      Leboeuf L, Tellez CA, Ead D, Gousse AE. Complication of bowel perforation during insertion of tension-free vaginal tape. J Urol 2003; 170:1310; discussion 1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/21\">",
"      Meschia M, Busacca M, Pifarotti P, De Marinis S. Bowel perforation during insertion of tension-free vaginal tape (TVT). Int Urogynecol J Pelvic Floor Dysfunct 2002; 13:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/22\">",
"      Castillo OA, Bodden E, Olivares RA, Urena RD. Intestinal perforation: an infrequent complication during insertion of tension-free vaginal tape. J Urol 2004; 172:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/23\">",
"      Daneshgari F, Kong W, Swartz M. Complications of mid urethral slings: important outcomes for future clinical trials. J Urol 2008; 180:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/24\">",
"      Kaelin-Gambirasio I, Jacob S, Boulvain M, et al. Complications associated with transobturator sling procedures: analysis of 233 consecutive cases with a 27 months follow-up. BMC Womens Health 2009; 9:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/25\">",
"      Elzevier HW, Putter H, Delaere KP, et al. Female sexual function after surgery for stress urinary incontinence: transobturator suburethral tape vs. tension-free vaginal tape obturator. J Sex Med 2008; 5:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/26\">",
"      Sentilhes L, Berthier A, Loisel C, et al. Female sexual function following surgery for stress urinary incontinence: tension-free vaginal versus transobturator tape procedure. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/27\">",
"      Pickens RB, Klein FA, Mobley JD 3rd, White WM. Single incision mid-urethral sling for treatment of female stress urinary incontinence. Urology 2011; 77:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/28\">",
"      Lee KS, Lee YS, Seo JT, et al. A prospective multicenter randomized comparative study between the U- and H-type methods of the TVT SECUR procedure for the treatment of female stress urinary incontinence: 1-year follow-up. Eur Urol 2010; 57:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/29\">",
"      Kennelly MJ, Moore R, Nguyen JN, et al. Prospective evaluation of a single incision sling for stress urinary incontinence. J Urol 2010; 184:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/30\">",
"      Serels S, Douso M, Duoso M, Short G. Preliminary findings with the Solyx single-incision sling system in female stress urinary incontinence. Int Urogynecol J 2010; 21:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/31\">",
"      Debodinance P, Delporte P. [Miniarc : prospective study and follow up at one year about 72 patients]. J Gynecol Obstet Biol Reprod (Paris) 2010; 39:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/32\">",
"      Moore RD, Mitchell GK, Miklos JR. Single-center retrospective study of the technique, safety, and 12-month efficacy of the MiniArc&trade; single-incision sling: a new minimally invasive procedure for treatment of female SUI. Surg Technol Int 2009; 18:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/33\">",
"      North CE, Hilton P, Ali-Ross NS, Smith AR. A 2-year observational study to determine the efficacy of a novel single incision sling procedure (Minitape) for female stress urinary incontinence. BJOG 2010; 117:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/34\">",
"      Hinoul P, Vervest HA, den Boon J, et al. A randomized, controlled trial comparing an innovative single incision sling with an established transobturator sling to treat female stress urinary incontinence. J Urol 2011; 185:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/35\">",
"      Tommaselli GA, Di Carlo C, Gargano V, et al. Efficacy and safety of TVT-O and TVT-Secur in the treatment of female stress urinary incontinence: 1-year follow-up. Int Urogynecol J 2010; 21:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/36\">",
"      Barber MD, Weidner AC, Sokol AI, et al. Single-incision mini-sling compared with tension-free vaginal tape for the treatment of stress urinary incontinence: a randomized controlled trial. Obstet Gynecol 2012; 119:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/37\">",
"      Basu M, Duckett J. A randomised trial of a retropubic tension-free vaginal tape versus a mini-sling for stress incontinence. BJOG 2010; 117:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16055/abstract/38\">",
"      Araco F, Gravante G, Dati S, et al. Results 1 year after the Reemex system was applied for the treatment of stress urinary incontinence caused by intrinsic sphincter deficiency. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:783.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15908 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16055=[""].join("\n");
var outline_f15_43_16055=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2822622\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2822614\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2823335\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H497779\">",
"      FULL LENGTH SLINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2822326\">",
"      Transobturator versus retropubic midurethral slings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H497696\">",
"      Choosing a type of retropubic sling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H497704\">",
"      Choosing a type of transobturator sling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2823271\">",
"      SINGLE INCISION SLINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H497737\">",
"      Single incision versus full-length slings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2823278\">",
"      Adjustable slings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2822622\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/15908\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/15908|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/0/31744\" title=\"figure 1\">",
"      Location of retropubic midurethral sling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/43/32432\" title=\"figure 2\">",
"      Location of transobturator midurethral sling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/42/16034\" title=\"figure 3\">",
"      Sling placement",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/56/35714?source=related_link\">",
"      Patient information: Surgery to treat stress urinary incontinence in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/8/22658?source=related_link\">",
"      Patient information: Urinary incontinence (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=related_link\">",
"      Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=related_link\">",
"      Stress urinary incontinence in women: Choosing a primary surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44409?source=related_link\">",
"      Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33562?source=related_link\">",
"      Stress urinary incontinence in women: Retropubic midurethral slings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33401?source=related_link\">",
"      Stress urinary incontinence in women: Transobturator midurethral slings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_43_16056="Clinical manifestations of hypothermia in children";
var content_f15_43_16056=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of hypothermia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/43/16056/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16056/contributors\">",
"     Howard M Corneli, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16056/contributors\">",
"     Robert G Bolte, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/43/16056/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16056/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/43/16056/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16056/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/43/16056/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia in children presents several challenges. It is common enough that clinicians will need to recognize and treat it, but uncommon enough that the details of care may be hard to recall. The diagnosis is surprisingly easy to overlook, and its treatment alters some standard practices. Although generally harmful, severe (and rapid) hypothermia may also provide cerebral protection against anoxia, allowing cases of remarkable survival after cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of unintentional hypothermia in children will be reviewed here. Treatment of hypothermia in children, neonatal hypothermia, and frostbite are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7530?source=see_link\">",
"     \"Treatment of hypothermia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=see_link&amp;anchor=H6#H6\">",
"     \"Short-term complications of the premature infant\", section on 'Hypothermia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37671?source=see_link\">",
"     \"Frostbite\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF HYPOTHERMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia is defined as a core body temperature below 35&ordm;C (95&ordm;F). The stage of hypothermia, defined by core temperature, has a large impact on both recognition and treatment. The most commonly used definitions found in the literature are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mild",
"      </strong>",
"      - Core temperature 32 to 35&ordm;C (90 to 95&ordm;F)",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate",
"      </strong>",
"      - Core temperature 28 to 32&ordm;C (82 to 90&ordm;F)",
"     </li>",
"     <li>",
"      <strong>",
"       Severe",
"      </strong>",
"      - Core temperature below 28&ordm;C (82&ordm;F)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, some experts regard a core temperature &lt;20&ordm;C (68&ordm;F) as profound hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other published cutoffs are similar [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/7\">",
"     7",
"    </a>",
"    ]. Because the clinical features of hypothermia differ somewhat among patients, and because core temperature measurement is imprecise, the recognition of each stage is more important than its exact boundaries. Clinicians, while carefully measuring core temperatures, may also refer to the clinical staging described by the International Commission for Mountain Emergency Medicine (",
"    <a class=\"graphic graphic_table graphicRef88073 \" href=\"UTD.htm?0/5/86\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mild (HT I)",
"      </strong>",
"      &ndash; Normal mental status with shivering",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate (HT II)",
"      </strong>",
"      &ndash; Altered mental status without shivering",
"     </li>",
"     <li>",
"      <strong>",
"       Severe (HT III)",
"      </strong>",
"      &ndash; Coma without shivering, vital signs present",
"     </li>",
"     <li>",
"      <strong>",
"       Severe (HT IV)",
"      </strong>",
"      &ndash; No vital signs, resuscitation possible",
"     </li>",
"     <li>",
"      <strong>",
"       Death (HT V)",
"      </strong>",
"      &ndash; Irreversible hypothermia, resuscitation not possible (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7530?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of hypothermia in children\", section on 'Prehospital declaration of death'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;From 1979 to 1998, the Centers for Disease Control recorded 14,000 deaths from hypothermia in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/9\">",
"     9",
"    </a>",
"    ]: The total number of cases is likely much larger because the diagnosis is often missed. Classic exposure, such as rescue from icy water, is typically recognized. However, hypothermia associated directly or indirectly with causes, such as trauma, underlying medical illness, or child abuse may be overlooked. Among children, infants are most susceptible to hypothermia. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pathophysiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physics of heat loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat is lost from the body by radiation, conduction, convection, evaporation, and respiration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/10\">",
"     10",
"    </a>",
"    ]. Of these, radiation normally accounts for up to 50 percent of heat loss, even in indoor settings [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/11\">",
"     11",
"    </a>",
"    ]. Convection may account for 25 percent of heat loss even in still air, and wind rapidly increases convective losses. Wet clothing increases evaporation; in severe conditions, evaporative heat loss may be six times basal metabolic heat production. Conduction, although low in air, is approximately 25 times more rapid in water. Finally, cooling during rescue and resuscitation is promoted by continued exposure, respiratory heat loss, and the infusion of room temperature fluids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pediatric considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children are at greater risk for hypothermia than adults for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The younger the child, the smaller the ratio of body mass to surface area, leading to increased heat loss.",
"     </li>",
"     <li>",
"      Children may have decreased ability to recognize or avoid dangerous environmental conditions.",
"     </li>",
"     <li>",
"      Young children have limited glycogen stores to support increased heat production in response to cold.",
"     </li>",
"     <li>",
"      Very young infants do not have the ability to increase heat production through shivering.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once hypothermic, young children may be more likely than adults to have good neurologic outcomes despite severe or profound hypothermia. This neuroprotective effect appears to depend on a combination of rapid cooling and preserved circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physiologic changes with stages of hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stages of hypothermia correspond to the body's changing physiologic responses to cold (",
"    <a class=\"graphic graphic_table graphicRef70617 \" href=\"UTD.htm?5/31/5628\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In mild hypothermia, the body attempts to combat heat loss by using shivering, vasoconstriction, and an increased metabolism. Consciousness is preserved.",
"   </p>",
"   <p>",
"    Moderate hypothermia spans a narrow range in which these compensatory mechanisms begin to fail. Changes may include lack of shivering, respiratory depression, decrease in metabolism, circulatory insufficiency and instability, vasodilation, hypovolemia, and impaired consciousness, including lethargy, confusion, and possible &ldquo;paradoxical undressing&rdquo; or other irrational behavior.",
"   </p>",
"   <p>",
"    In severe hypothermia, the metabolic machinery underlying body function is suppressed or arrested by cold. Patients usually become unconscious and vital signs may or may not be present. Muscle rigidity without shivering occurs. The metabolism slows by approximately 6 percent for each 1&deg;C (1.8&deg;F) decrease in body temperature, such that at 28&deg;C (82&deg;F) the basal metabolic rate is approximately half of the normal rate. At this temperature, all body functions begin to fail including circulation, ventilation, and central nervous system function.",
"   </p>",
"   <p>",
"    It is also in this stage of severe hypothermia (core temperature &lt;28&deg;C or 82&deg;F) that some patients benefit from the protection against hypoxia conferred by a suspended metabolism. Patients have tolerated anoxia for 12 to 18 minutes at 28&deg;C (82&deg;F) and up to 60 minutes or more at 20&deg;C (68&deg;F) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/13\">",
"     13",
"    </a>",
"    ]. Hypothermia in such patients may offer some hope of successful recovery despite the absence of effective circulation and the presence of clinical signs of death. This fact alters the rules of treatment and the declaration of death in cases of severe hypothermia; it also underscores the need for rapid, effective rewarming and vigorous patient support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7530?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of hypothermia in children\", section on 'Prehospital declaration of death'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7530?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of hypothermia in children\", section on 'Treatment of moderate or severe hypothermia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cerebral protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients benefit from cerebral protection in hypothermia. Rapid or profound cooling before circulatory arrest may favor such protection; slow or incomplete cooling in the presence of critical hypoxia or circulatory failure may cause anoxic brain damage before protection is possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other physiologic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The other extensive physiologic changes in hypothermia are all harmful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiration progressively becomes slow, shallow, irregular, and then absent.",
"     </li>",
"     <li>",
"      Blood volume markedly decreases because of extravasation due to vascular leak and a profound \"cold diuresis\" caused by erroneous signaling to the kidney about blood volume. Cold diuresis is worsened by failure of renal concentrating function. The hydrostatic effects of immersion also promote shock after water rescue [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac output is reduced by hypovolemia, sludging of blood due to cold, decreased myocardial contractility, and bradycardia. In addition, vasodilation due to loss of vasomotor regulation drops systemic vascular resistance. All of these effects contribute to circulatory collapse.",
"     </li>",
"     <li>",
"      Hypothermia increases myocardial irritability. Thus, ventricular fibrillation (VF) is a frequent problem in severe hypothermia [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/15\">",
"       15",
"      </a>",
"      ]. Potential triggers of VF to be avoided during treatment include rough patient handling, patient exertion, core temperature afterdrop (further cooling of the body after being removed from cold exposure), administration of room-temperature fluids, direct stimulation of the myocardium (eg, subclavian central lines, and rewarming shock). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7530?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of hypothermia in children\", section on 'Initial hospital care'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7530?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of hypothermia in children\", section on 'Active external rewarming'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Variable effects of hypothermia may include thrombocytopenia, coagulopathy, hyperkalemia, hypo- or hyperglycemia, and metabolic acidosis or alkalosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features vary with the stage of hypothermia (",
"    <a class=\"graphic graphic_table graphicRef62978 \" href=\"UTD.htm?0/15/252\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the temperature of onset for these findings may differ in individual patients. This is especially true for mental status changes and cardiac arrhythmias. In children with moderate or severe hypothermia, the signs of hypothermia actually become less obvious. The urgency of cardiorespiratory failure or coma may cause the clinician to overlook hypothermia. Early measurement of core body temperature is essential to establish the diagnosis. (See",
"    <a class=\"local\" href=\"#H1685770\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hypothermia causes the heart to be very sensitive to further cooling or decreases in central venous pH associated with abrupt movement or rough handling of the patient. These changes may precipitate cardiac arrhythmias, including ventricular fibrillation. Thus, avoidance of continued cooling and gentle patient handling is recommended during evaluation.",
"   </p>",
"   <p>",
"    Clinical features of hypothermia by stage are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mild hypothermia",
"      </strong>",
"      &ndash; Between approximately 32 and 35&deg;C (90 to 95&deg;F), the child may display shivering, piloerection (\"goose bumps\"), and peripheral vasoconstriction with prolonged capillary refill time, pallor, and acrocyanosis. These changes all arise from physiologic mechanisms designed to preserve core body temperature. Of note, young infants primarily preserve heat by intense peripheral vasoconstriction, have limited ability to shiver, and are less able to maintain body heat than older children. Consciousness is typically preserved.",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate hypothermia",
"      </strong>",
"      &ndash; Mental function may begin to be impaired between 28 and 32&deg;C (82 to 90&deg;F). Slurred speech, clumsy movements, and impaired thinking may produce a picture of intoxication, thus hindering recognition of hypothermia. In general, agitation and distress give way to confusion and lethargy as core body temperature continues to drop. As hypothermia progresses, shivering stops, and heart rate, ventilation, and blood pressure become variable and then depressed.",
"     </li>",
"     <li>",
"      <strong>",
"       Severe hypothermia",
"      </strong>",
"      &ndash; Below approximately 28&deg;C (82&deg;F) the appearance of hypothermia becomes less obvious, because shivering and pallor give way to muscle rigidity and flushed skin. Patients with such muscle rigidity may be described as \"frozen stiff\", but freezing doesn't occur above a core body temperature of 0&deg;C (32&deg;F). Rather, this rigidity reflects dysfunction of actin-myosin bundles within skeletal muscle.",
"      <br/>",
"      <br/>",
"      Bradycardia and hypotension progress to pulselessness, ventricular fibrillation, or asystole. Although ventricular fibrillation or asystole are endpoint rhythms in hypothermia, a number of other rhythms may be seen (eg, sinus bradycardia, atrioventricular blockade, atrial fibrillation, junctional rhythm) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/16\">",
"       16",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Stupor gives way to unresponsive coma with fixed and dilated pupils. Thus, the severely or profoundly hypothermic patient may appear dead.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1687020\">",
"    <span class=\"h1\">",
"     ANCILLARY STUDIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of hypothermia on laboratory evaluation is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=see_link&amp;anchor=H10#H10\">",
"     \"Accidental hypothermia in adults\", section on 'Laboratory studies and monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=see_link&amp;anchor=H11#H11\">",
"     \"Arterial blood gases\", section on 'Analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Previously healthy children with mild hypothermia from environmental exposure may not require any laboratory testing. However, in patients with moderate to severe hypothermia, low body temperature directly alters several laboratory measurements, and the following studies should be obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rapid serum glucose",
"     </li>",
"     <li>",
"      Serum electrolytes",
"     </li>",
"     <li>",
"      Serum blood urea nitrogen and creatinine",
"     </li>",
"     <li>",
"      Lipase",
"     </li>",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR)",
"     </li>",
"     <li>",
"      Blood type and crossmatch studies (if the need for extracorporeal warming is anticipated)",
"     </li>",
"     <li>",
"      Arterial blood gas",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Capillary blood gas samples are likely to be misleading in children with hypothermia, because the peripheral circulation is poor, and the resulting blood gas will not accurately reflect overall acid base status. Poor circulation may at times interfere with pulse oximetry. The presence of a good waveform and other measures of clinical correlation should be confirmed. Central venous blood gas measurements may be an appropriate proxy for arterial pH and pCO2 measurements.",
"   </p>",
"   <p>",
"    Additional studies may be necessary depending upon clinical circumstances. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Trauma",
"      </strong>",
"      &ndash; In children with multisystem trauma or possible child abuse, urine rapid dipstick for blood, liver enzymes (AST, ALT), and blood for typing and cross match may be indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H22#H22\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Laboratory studies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link&amp;anchor=H6#H6\">",
"       \"Physical abuse in children: Diagnostic evaluation and management\", section on 'Laboratory evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Sepsis",
"      </strong>",
"      &ndash; Urine, blood, and CSF culture should be obtained in young infants with ill appearance and mild to moderate hypothermia or hypothermia when sepsis is suspected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=see_link&amp;anchor=H13#H13\">",
"       \"Approach to the septic-appearing infant\", section on 'Laboratory studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Intoxication",
"      </strong>",
"      &ndash; Urinalysis, serum osmolality, ethanol level, urine screen for drugs of abuse (especially, benzodiazepines, opioids, and barbiturates) should be performed in children and adolescents at risk for intoxication. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link&amp;anchor=H13#H13\">",
"       \"Approach to the child with occult toxic exposure\", section on 'Ancillary studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Unexplained or resistant hypothermia",
"      </strong>",
"      &ndash; Thyroxine (T4), thyroid stimulating hormone, adrenocorticotropic hormone (ACTH), and serum cortisol should be measured in patients with unexplained mild hypothermia or those who are resistant to rewarming. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=see_link&amp;anchor=H21#H21\">",
"       \"Accidental hypothermia in adults\", section on 'Failure to rewarm'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 12 lead ECG should be obtained in all hypothermic patients, and ongoing monitoring of cardiac rhythm should occur during treatment. The development of ventricular fibrillation (VF), pulseless electrical activity (PEA), or asystole is common during resuscitation of children with severe hypothermia. The spontaneous conversion of asystole to VF, and of VF to sinus rhythm may occur during effective rewarming [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/3,17\">",
"     3,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypothermia causes characteristic ECG changes because of slowed impulse conduction through potassium channels. This effect results in prolongation of all the ECG intervals, including RR, PR, QRS, and QT.",
"   </p>",
"   <p>",
"    There may also be elevation of the J point, producing a characteristic J or Osborn wave that represents distortion of the earliest phase of membrane repolarization (",
"    <a class=\"graphic graphic_waveform graphicRef64520 \" href=\"UTD.htm?41/38/42602\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef56369 \" href=\"UTD.htm?29/22/30051\">",
"     waveform 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Available software for ECG interpretation is",
"    <strong>",
"     unable",
"    </strong>",
"    to recognize Osborn waves, and often misinterprets them as currents of injury (ie, ischemic changes). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=see_link&amp;anchor=H11#H11\">",
"     \"Accidental hypothermia in adults\", section on 'Electrocardiographic changes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Shivering can cause a rhythmic irregularity of the ECG baseline, and occasionally the QRS complex (",
"    <a class=\"graphic graphic_waveform graphicRef62575 \" href=\"UTD.htm?41/24/42374\">",
"     waveform 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiologic studies in hypothermia are performed based upon specific indications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Abnormal lung examination",
"      </strong>",
"      &ndash; Children with abnormal pulmonary findings (eg, tachypnea, cough, and rales), history of chest trauma, near-drowning, or moderate to severe hypothermia warrant chest radiographs to detect signs of aspiration, bronchopneumonia, pulmonary injury, or pulmonary edema.",
"     </li>",
"     <li>",
"      <strong>",
"       Multisystem trauma",
"      </strong>",
"      &ndash; Victims of multisystem trauma with associated hypothermia should have appropriate imaging based upon the degree of trauma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H23#H23\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Screening radiographs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Diving injury",
"      </strong>",
"      &ndash; Patients with near-drowning in association with a possible diving injury should have radiographic evaluation for cervical spine injury. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"       \"Evaluation of cervical spine injuries in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Child abuse",
"      </strong>",
"      &ndash; Children under two years of age with physical findings suggestive of child abuse and older children with unexplained fractures should undergo a skeletal survey. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link&amp;anchor=H6#H6\">",
"       \"Orthopedic aspects of child abuse\", section on 'Radiographic evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1685770\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia should be suspected not only in patients who have had an environmental exposure to cold, but also in those who are seriously ill or injured. Hypothermia is diagnosed by identification of a core body temperature that is &lt;35&ordm;C (95&ordm;F) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, the accurate measurement of core body temperature in children with hypothermia is essential to proper diagnosis; children with suspected hypothermia should have their temperature taken with a low-reading rectal probe thermometer or, ideally, the core temperature should be measured using nasopharyngeal, esophageal, bladder, or central venous catheter temperature probes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/10,20\">",
"     10,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinician should be aware of the following limitations to accurate temperature measurements with these devices [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rectal temperature may lag behind core body temperature measured centrally, sometimes severely. When possible, other central sites for temperature measurement are preferred.",
"     </li>",
"     <li>",
"      Rectal and bladder probe readings may increase with peritoneal lavage.",
"     </li>",
"     <li>",
"      Nasopharyngeal and esophageal probe readings may increase from warm air transmitted through the trachea",
"     </li>",
"     <li>",
"      Esophageal probe readings may increase during left pleural lavage.",
"     </li>",
"     <li>",
"      Central venous probe readings may rise during rapid infusion of heated fluids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician should",
"    <strong>",
"     not",
"    </strong>",
"    use standard clinical thermometers in hypothermic patients because they do not read below 34&ordm;C (93&ordm;F). In addition, the oral, axillary, infrared, and indirect tympanic membrane sites are unreliable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=see_link&amp;anchor=H703490142#H703490142\">",
"     \"Pathophysiology and management of fever in infants and children\", section on 'Temperature measurement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although true tympanic temperatures may closely reflect core temperatures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/21\">",
"     21",
"    </a>",
"    ], indirect infrared tympanic thermometers, typically available in the emergency department, are subject to artifact after cold water exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/22\">",
"     22",
"    </a>",
"    ] and have not been shown to be reliable in patients with moderate or severe hypothermia.",
"   </p>",
"   <p>",
"    When core temperature assessment is not readily available, assessment of shivering, level of consciousness, and vital signs provide a means of estimating the initial stage of hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/6,8\">",
"     6,8",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef88073 \" href=\"UTD.htm?0/5/86\">",
"     table 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Young infants, neonates, and children with predisposing conditions (eg multisystem trauma, burns, congenital nervous system anomalies, anorexia nervosa, or drug overdose) are at particular risk, even when the ambient temperature is moderate. (See",
"    <a class=\"local\" href=\"#H9285874\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9285874\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia may arise from environmental exposure, trauma, medical conditions, or a combination of these factors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/6\">",
"     6",
"    </a>",
"    ]. Medical conditions commonly associated with hypothermia in children include hypoglycemia, hyponatremia, central nervous system pathology (eg, craniopharyngioma, absence of the corpus callosum, intracranial bleeding), endocrine disease (eg, hypothyroidism or adrenal insufficiency), malnutrition, anorexia nervosa, burns, and drug overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/10,23\">",
"     10,23",
"    </a>",
"    ]. These and other pediatric etiologies of hypothermia can be organized by pathophysiology as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef88088 \" href=\"UTD.htm?10/24/10637\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The hypothermia in patients with medical conditions as a primary cause is typically mild on presentation (core body temperature 32 to 35&ordm;C [90 to 95&ordm;F]) and occurs without environmental exposure. However, patients with these medical conditions are predisposed to more severe degrees of hypothermia with exposure to temperate or cold weather. In such patients, an underlying medical cause may be apparent by clinical or laboratory findings or may be suggested by a clinical course notable for resistance to rewarming.",
"   </p>",
"   <p>",
"    Certain aspects of specific etiologies warrant emphasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Environmental exposure",
"      </strong>",
"      &ndash; Hypothermia occurs even in warm climates, such as the southern US, where cold-related deaths may be twice as common as those due to heat [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/24\">",
"       24",
"      </a>",
"      ]. Any child may develop hypothermia when exposed to wet, cool, or windy conditions, even when ambient temperature is moderate.",
"     </li>",
"     <li>",
"      <strong>",
"       Trauma and resuscitation",
"      </strong>",
"      &ndash; Beyond the risk of exposure, common causes of hypothermia include injury, transport, and resuscitation, even in warm climates [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/25\">",
"       25",
"      </a>",
"      ], and especially in infants and young children [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/26\">",
"       26",
"      </a>",
"      ]. Hypothermia is especially common in settings where environmental exposure is prolonged (eg, motor vehicle collision in winter with prolonged extrication). Patients with traumatic brain or spinal cord injury are also at risk for hypothermia because of potential damage to central and autonomic thermoregulatory systems. Thus, multisystem trauma patients warrant early measurement of core temperature during resuscitation and efforts to prevent heat loss. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H20#H20\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Exposure and environment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Sepsis",
"      </strong>",
"      &ndash; Sepsis may present as mild hypothermia, especially in young infants and older children with immunosuppression or chronic medical conditions (eg, cerebral palsy with spastic quadriplegia and developmental delay). Often, these patients are ill-appearing and have clinical findings (eg, lethargy, hypotension, widened pulse pressure) that cannot be attributed to mild hypothermia. These patients warrant appropriate cultures (urine, blood, and cerebrospinal fluid), fluid resuscitation, and intravenous antibiotics targeted to the most likely infectious etiology based on age and epidemiologic considerations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H4570172#H4570172\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Systemic inflammatory response syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Medications and toxins",
"      </strong>",
"      &ndash; Medications and toxins associated with hypothermia may cause vasodilation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      altered mental status. Both effects increase the likelihood of environmental hypothermia and hasten heat loss. For example, hypothermia may accompany overdose of ethanol, benzodiazepines, opioids,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"       clonidine",
"      </a>",
"      , typical antipsychotic medications (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/35/21047?source=see_link\">",
"       chlorpromazine",
"      </a>",
"      ), and cyclic antidepressant medications (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/32/7687?source=see_link\">",
"       amitriptyline",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      In adolescents, a common scenario involves a teenager engaging in recreational drug use in an outdoor setting (eg, rock concert, camping trip) who becomes disoriented or passes out and then becomes hypothermic.",
"     </li>",
"     <li>",
"      <strong>",
"       Skin",
"      </strong>",
"      &ndash; Thermal and chemical burns as well as weeping dermatoses may promote significant heat loss, especially in children.",
"     </li>",
"     <li>",
"      <strong>",
"       Child abuse and neglect",
"      </strong>",
"      &ndash; Child abuse in cases of hypothermia may be easily missed. Cold immersion or near-drowning have been noted as forms of child abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. Malnutrition, neglect, abandonment, and forced intoxication are among other causes [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16056/abstract/29\">",
"       29",
"      </a>",
"      ]. Suspicion should be raised not only by signs of abuse but also by questions of neglect or an inconsistent history. Post-mortem cooling develops slowly, so that unusual hypothermia after a recent arrest may represent child abuse. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"       \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18408?source=see_link\">",
"       \"Child neglect and emotional abuse\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/6/109?source=see_link\">",
"       \"Patient information: Hypothermia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of hypothermia in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7530?source=see_link\">",
"     \"Treatment of hypothermia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypothermia is defined as a core body temperature below 35&ordm;C (95&ordm;F). The most commonly used definitions found in the literature are as follows (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of hypothermia'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Mild",
"      </strong>",
"      - Core temperature 32 to 35&ordm;C (90 to 95&ordm;F)",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate",
"      </strong>",
"      - Core temperature 28 to 32&ordm;C (82 to 90&ordm;F)",
"     </li>",
"     <li>",
"      <strong>",
"       Severe",
"      </strong>",
"      - Core temperature below 28&ordm;C (82&ordm;F). These stages of hypothermia approximate the body's changing physiologic responses to cold (",
"      <a class=\"graphic graphic_table graphicRef70617 \" href=\"UTD.htm?5/31/5628\">",
"       table 2",
"      </a>",
"      ) and thus, suggest important differences not only in severity but also in treatment and rewarming. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In prehospital settings where obtaining a core temperature measurement is challenging, the degree of hypothermia can be estimated from clinical findings (",
"      <a class=\"graphic graphic_table graphicRef88073 \" href=\"UTD.htm?0/5/86\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of hypothermia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children are at greater risk for hypothermia than adults especially because their small body mass relative to surface area causes increased heat loss. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7530?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of hypothermia in children\", section on 'Passive rewarming'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The accurate measurement of core body temperature in children with hypothermia is essential to proper diagnosis. Thus, children with suspected hypothermia should have their temperature initially taken with a low-reading rectal probe thermometer or, ideally, true core temperature should be measured using nasopharyngeal, esophageal, bladder, or central venous catheter temperature probes. (See",
"      <a class=\"local\" href=\"#H1685770\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical features seen in hypothermia vary by temperature (",
"      <a class=\"graphic graphic_table graphicRef62978 \" href=\"UTD.htm?0/15/252\">",
"       table 3",
"      </a>",
"      ). Severe hypothermia is less obvious than mild or moderate hypothermia. (See",
"      <a class=\"local\" href=\"#H1685770\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The severely hypothermic child may appear dead but still have significant potential for intact survival with proper resuscitation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Pediatric considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Previously healthy children with mild hypothermia from environmental exposure may not require any laboratory testing. However, in patients with moderate to severe hypothermia, low body temperature directly alters several laboratory measurements. Moderate and severe hypothermia can also cause arrhythmias and prolongation of all electrocardiogram (EKG) intervals. Thus, selected studies and EKG are warranted as described above. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Laboratory studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Electrocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical conditions that can result in hypothermia in children include sepsis (especially in young infants or neonates), burns, hypothalamic disruption (eg, traumatic brain injury, congenital central nervous system anomalies), drug overdose, hyponatremia, adrenal insufficiency, anorexia nervosa, and malnutrition. An underlying medical cause may be obvious or may be suggested when hypothermia is resistant to rewarming (eg, sepsis, hypothyroidism, adrenal insufficiency). (See",
"      <a class=\"local\" href=\"#H9285874\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/1\">",
"      Beilman GJ, Blondet JJ, Nelson TR, et al. Early hypothermia in severely injured trauma patients is a significant risk factor for multiple organ dysfunction syndrome but not mortality. Ann Surg 2009; 249:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/2\">",
"      Walpoth BH, Walpoth-Aslan BN, Mattle HP, et al. Outcome of survivors of accidental deep hypothermia and circulatory arrest treated with extracorporeal blood warming. N Engl J Med 1997; 337:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/3\">",
"      Bolte RG, Black PG, Bowers RS, et al. The use of extracorporeal rewarming in a child submerged for 66 minutes. JAMA 1988; 260:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/4\">",
"      Giesbrecht GG. Cold stress, near drowning and accidental hypothermia: a review. Aviat Space Environ Med 2000; 71:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/5\">",
"      Jolly BT, Ghezzi KT. Accidental hypothermia. Emerg Med Clin North Am 1992; 10:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/6\">",
"      Brown DJ, Brugger H, Boyd J, Paal P. Accidental hypothermia. N Engl J Med 2012; 367:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/7\">",
"      2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Part 10.4: Hypothermia. Circulation 2005; 112:IV.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/8\">",
"      Durrer B, Brugger H, Syme D, International Commission for Mountain Emergency Medicine. The medical on-site treatment of hypothermia: ICAR-MEDCOM recommendation. High Alt Med Biol 2003; 4:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/9\">",
"      From the Centers for Disease Control and Prevention. Hypothermia-related deaths--Utah, 2000, and United States, 1979-1998. JAMA 2002; 287:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/10\">",
"      Corneli HM. Accidental hypothermia. J Pediatr 1992; 120:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/11\">",
"      English MJ, Farmer C, Scott WA. Heat loss in exposed volunteers. J Trauma 1990; 30:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/12\">",
"      Bierens JJ, van der Velde EA, van Berkel M, van Zanten JJ. Submersion in The Netherlands: prognostic indicators and results of resuscitation. Ann Emerg Med 1990; 19:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/13\">",
"      Wagner HR, Subramanian S. Deep hypothermia in infant cardiac surgery. Pediatrics 1978; 61:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/14\">",
"      Golden FS, Hervey GR, Tipton MJ. Circum-rescue collapse: collapse, sometimes fatal, associated with rescue of immersion victims. J R Nav Med Serv 1991; 77:139.",
"     </a>",
"    </li>",
"    <li>",
"     Corneli HM. Ventricular fibrillation from hypothermia. In: Ventricular Fibrillation: A Pediatric Problem, Quan L, Franklin WH.  (Eds), Futura, Armonk 2000. p.69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/16\">",
"      Solomon A, Barish RA, Browne B, Tso E. The electrocardiographic features of hypothermia. J Emerg Med 1989; 7:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/17\">",
"      Gilbert M, Busund R, Skagseth A, et al. Resuscitation from accidental hypothermia of 13.7 degrees C with circulatory arrest. Lancet 2000; 355:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/18\">",
"      Mattu A, Brady WJ, Perron AD. Electrocardiographic manifestations of hypothermia. Am J Emerg Med 2002; 20:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/19\">",
"      Aslam AF, Aslam AK, Vasavada BC, Khan IA. Hypothermia: evaluation, electrocardiographic manifestations, and management. Am J Med 2006; 119:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/20\">",
"      Maxton FJ, Justin L, Gillies D. Estimating core temperature in infants and children after cardiac surgery: a comparison of six methods. J Adv Nurs 2004; 45:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/21\">",
"      Harasawa K, Kemmotsu O, Mayumi T, Kawano Y. Comparison of tympanic, esophageal and blood temperatures during mild hypothermic cardiopulmonary bypass: a study using an infrared emission detection tympanic thermometer. J Clin Monit 1997; 13:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/22\">",
"      Rogers IR, Brannigan D, Montgomery A, et al. Tympanic thermometry is unsuitable as a screening tool for hypothermia after open water swimming. Wilderness Environ Med 2007; 18:218.",
"     </a>",
"    </li>",
"    <li>",
"     Tunnessen WW, Roberts KB. Hypothermia. In: Signs and Symptoms in Pediatrics, 3rd edition, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.8.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/24\">",
"      Taylor AJ, McGwin G Jr. Temperature-related deaths in Alabama. South Med J 2000; 93:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/25\">",
"      Aitken LM, Hendrikz JK, Dulhunty JM, Rudd MJ. Hypothermia and associated outcomes in seriously injured trauma patients in a predominantly sub-tropical climate. Resuscitation 2009; 80:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/26\">",
"      Hickey RW, Kochanek PM, Ferimer H, et al. Hypothermia and hyperthermia in children after resuscitation from cardiac arrest. Pediatrics 2000; 106:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/27\">",
"      Gillenwater JM, Quan L, Feldman KW. Inflicted submersion in childhood. Arch Pediatr Adolesc Med 1996; 150:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/28\">",
"      Lavelle JM, Shaw KN, Seidl T, Ludwig S. Ten-year review of pediatric bathtub near-drownings: evaluation for child abuse and neglect. Ann Emerg Med 1995; 25:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16056/abstract/29\">",
"      Medani CR. Seizures and hypothermia due to dietary water intoxication in infants. South Med J 1987; 80:421.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6597 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16056=[""].join("\n");
var outline_f15_43_16056=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF HYPOTHERMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physics of heat loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pediatric considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physiologic changes with stages of hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cerebral protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other physiologic effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1687020\">",
"      ANCILLARY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1685770\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9285874\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6597\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6597|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/5/86\" title=\"table 1\">",
"      ICAR-MEDCOM hypothermia scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/31/5628\" title=\"table 2\">",
"      Hypothermia physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/15/252\" title=\"table 3\">",
"      Clinical findings by stage of hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/24/10637\" title=\"table 4\">",
"      Conditions causing hypothermia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6597|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/38/42602\" title=\"waveform 1\">",
"      Osborn waves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?29/22/30051\" title=\"waveform 2\">",
"      J wave",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/24/42374\" title=\"waveform 3\">",
"      Tremor artifact tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=related_link\">",
"      Accidental hypothermia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=related_link\">",
"      Approach to the septic-appearing infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=related_link\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18408?source=related_link\">",
"      Child neglect and emotional abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37671?source=related_link\">",
"      Frostbite",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=related_link\">",
"      Orthopedic aspects of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=related_link\">",
"      Pathophysiology and management of fever in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/6/109?source=related_link\">",
"      Patient information: Hypothermia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=related_link\">",
"      Short-term complications of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7530?source=related_link\">",
"      Treatment of hypothermia in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_43_16057="Causes of bronchiectasis in children";
var content_f15_43_16057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of bronchiectasis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/43/16057/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16057/contributors\">",
"     Khoulood Fakhoury, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16057/contributors\">",
"     Adaobi Kanu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/43/16057/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16057/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/43/16057/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16057/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/43/16057/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchiectasis is a structural abnormality characterized by abnormal dilation and distortion of the bronchial tree, resulting in chronic obstructive lung disease. This condition is typically the end result of a variety of pathophysiologic processes that render the bronchial walls weakened, easily collapsible, chronically inflamed, and plugged with mucus secretions.",
"   </p>",
"   <p>",
"    In developed nations, cystic fibrosis (CF) is the most common cause of bronchiectasis in children. The evaluation and management of CF-related bronchiectasis is discussed in detail in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bronchiectasis can be caused by a variety of disease processes other than CF, most of which include some combination of bronchial obstruction and infection. The types of disorders that cause bronchiectasis vary among populations and age groups. As examples, infections and acquired causes of bronchiectasis predominate in adults and in developing nations, whereas congenital anomalies of the airways or immune system are more prominent in children and industrialized nations.",
"   </p>",
"   <p>",
"    This topic review will outline the pathogenesis and main causes of non-CF related bronchiectasis in children. The evaluation and management of non-CF bronchiectasis in children, and the causes of bronchiectasis in adults are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44662?source=see_link\">",
"     \"Clinical manifestations and evaluation of bronchiectasis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/0/6150?source=see_link\">",
"     \"Management of bronchiectasis in children without cystic fibrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of non-CF related bronchiectasis in developed nations has gradually declined in recent decades, probably because of improvements in sanitation and housing, immunizations against respiratory illnesses (eg, measles and pertussis), and antibiotic use [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estimated prevalence of non-CF bronchiectasis in most populations in developed nations is low. As an example, non-CF bronchiectasis was diagnosed in only 4.2 per 100,000 young adults in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/3\">",
"     3",
"    </a>",
"    ]. Prevalence rates vary substantially depending on the method used for case identification. Use of high-resolution CT will detect milder disease, and result in higher prevalence estimates than strategies employing less sensitive forms of radiography.",
"   </p>",
"   <p>",
"    Some indigenous populations, including natives of Polynesia, Alaska, Australia, and New Zealand, have prevalence rates of as high as 15 per 1000 children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. The relatively high rates of non-CF bronchiectasis in these populations has been attributed to environmental conditions causing recurrent respiratory infections during childhood, or, in some cases, to heritable defects in immunity or pulmonary clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, induction of bronchiectasis requires two factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An infectious insult",
"     </li>",
"     <li>",
"      Impaired mucus clearance, airway obstruction, or a defect in host defense",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These vectors of injury can result in an inflammatory response characterized by neutrophil influx and cytokine (inflammatory mediator) release. As examples, proinflammatory mediators (eg, tumor necrosis factor alpha, interleukins 1B and 8) are elevated in the sputum of children with both cystic fibrosis (CF)-related and non-CF related bronchiectasis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/8\">",
"     8",
"    </a>",
"    ]. Molecular mechanisms that contribute to airway damage in bronchiectasis are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The continued cycle of infection, inflammation, and airway injury with impaired mucociliary clearance results in loss of the airway muscular and elastic components with dilation and distortion of the airways and increased sputum production. The airways become collapsible, limiting airflow, especially with forced expiration. The lung parenchyma is often involved, developing areas of atelectasis, emphysema, and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. In addition, there is marked hypertrophy of the bronchial vasculature, which is prone to rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic Reid classification divides bronchiectasis into three different patterns, based on gross histological appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cylindrical bronchiectasis, mildly uniform airway dilation",
"     </li>",
"     <li>",
"      Varicose bronchiectasis, focally dilated areas between narrowed segments [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/9,12\">",
"       9,12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Saccular bronchiectasis, balloon-like airway dilation with more disruption of lung parenchyma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The correlation of these patterns with clinical status, etiology, or pathophysiology is not well established [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/13\">",
"     13",
"    </a>",
"    ]. However, studies using high-resolution CT scan suggest that bronchiectasis may be a dynamic process, and that cylindrical bronchiectasis can be reversible if the underlying cause is successfully treated (eg, patients with atelectasis, infection, or a retained foreign body) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many other cases, bronchiectatic changes appear to be irreversible. Indeed, some authors propose that the term bronchiectasis be defined as the irreversible dilation of the cartilage-containing airways or bronchi [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term \"traction bronchiectasis\" is used to describe the radiological finding of airway widening without surrounding thickening or damage (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70396 \" href=\"UTD.htm?8/31/8688\">",
"     image 1",
"    </a>",
"    ). This usually is caused by other lung disease, such as interstitial fibrosis, which causes traction on the airway so that it is widened, simulating bronchiectasis. No clinical symptoms are attributed to this finding, although respiratory symptoms related to the underlying disease may be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\", section on 'Distribution'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of underlying disease processes can cause bronchiectasis; the cause should be determined whenever possible because this may direct treatment. However, in 25 to 38 percent of pediatric cases, an underlying cause could not be identified despite a thorough evaluation. Persistent bacterial bronchitis is a newly recognized entity that may account for some of these cases of bronchiectasis in which an underlying cause could not be determined. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The causes of bronchiectasis can be categorized by whether the distribution is localized (focal) or generalized (",
"    <a class=\"graphic graphic_table graphicRef71732 \" href=\"UTD.htm?11/39/11900\">",
"     table 1",
"    </a>",
"    ). This categorization can be helpful in targeting the evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44662?source=see_link\">",
"     \"Clinical manifestations and evaluation of bronchiectasis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The causes of bronchiectasis also can be categorized according to the underlying pathophysiology (",
"    <a class=\"graphic graphic_table graphicRef87712 \" href=\"UTD.htm?26/62/27630\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Congenital bronchiectasis",
"     </li>",
"     <li>",
"      Bronchial narrowing or obstruction",
"     </li>",
"     <li>",
"      Immunodeficiency",
"     </li>",
"     <li>",
"      Abnormal secretion clearance (leading to chronic airway infection)",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Other underlying disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Congenital bronchiectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two congenital disorders have been described in which the structural rigidity of the tracheobronchial tree is compromised, leading to congenital bronchiectasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Williams-Campbell syndrome is a rare congenital disorder characterized by deficient cartilage in the bronchial tree, causing generalized tracheobronchomalacia [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/17\">",
"       17",
"      </a>",
"      ]. Because the bronchial cartilage is absent or deficient, the segmental and subsegmental bronchi are dilated and collapse easily. Children typically present before three years of age with cough, wheezing, and recurrent febrile illness. Based on the few cases reported in the literature, the prognosis is variable.",
"     </li>",
"     <li>",
"      Congenital tracheobronchomegaly (Mounier-Kuhn syndrome) is a congenital disorder that is characterized by markedly dilated trachea and main bronchi, resulting in dynamic dilation and collapse during inspiration and exhalation. On pathologic examination, there is atrophy or absence of elastic tissue, and thinning of the muscular components of the airway. Outpouching of redundant mucosal tissue results in pooling of secretions and recurrent infection, leading to bronchiectasis. The clinical manifestations range from minimal disease to respiratory failure and death. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18088?source=see_link&amp;anchor=H3#H3\">",
"       \"Tracheomalacia and tracheobronchomalacia in adults\", section on 'Congenital'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2794234\">",
"    <span class=\"h2\">",
"     Bronchial narrowing or obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial obstruction or narrowing may result in poor mucociliary clearance and chronic infection, with subsequent development of bronchiectasis. This can be congenital or acquired:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2794249\">",
"    <span class=\"h3\">",
"     Congenital airway or bronchial obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of congenital bronchial obstruction include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital airway malacia (tracheomalacia and bronchomalacia) &mdash; These disorders can be caused by primary defects in the airway wall, or may be secondary to external compression by another structure, such as a vascular ring or sling or pulmonary artery dilatation. Occasionally, the obstruction is severe enough to lead to recurrent infections and bronchiectasis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link&amp;anchor=H11#H11\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\", section on 'Tracheomalacia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link&amp;anchor=H27#H27\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\", section on 'Bronchomalacia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tracheal or bronchial stenosis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchogenic cyst (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link&amp;anchor=H29#H29\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\", section on 'Bronchogenic cyst'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tracheal bronchus (ectopic bronchus) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link&amp;anchor=H21#H21\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\", section on 'Tracheal bronchus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchopulmonary sequestration (intralobar type) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29144?source=see_link\">",
"       \"Bronchopulmonary sequestration\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital pulmonary airway malformation (CPAM), formerly known as congenital cystic adenomatoid malformation (CCAM) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=see_link\">",
"       \"Congenital pulmonary airway (cystic adenomatoid) malformation\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2793993\">",
"    <span class=\"h3\">",
"     Acquired bronchial obstruction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Foreign body aspiration &mdash; The most common cause of endobronchial obstruction in children is foreign body aspiration, most often of food items that are not radio-opaque, such as peanuts [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/18\">",
"       18",
"      </a>",
"      ]. The child typically presents with a sudden onset of cough, which persists over time. The aspiration event may have occurred weeks or even months prior to presentation, so a history of choking may not be recalled. The clinical course can be complicated by pneumonia, pneumothorax, hemoptysis, and bronchiectasis (",
"      <a class=\"graphic graphic_algorithm graphicRef68288 \" href=\"UTD.htm?34/34/35374\">",
"       algorithm 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"       \"Airway foreign bodies in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mucoid impaction &mdash; A variety of disorders tend to cause mucus plugging. If the plugging is prolonged or recurrent, it can lead to bronchiectasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Middle lobe syndrome is a pattern of chronic or recurrent atelectasis that usually affects the right middle or left lingular lobes of the lung. In children, it is usually seen in asthmatics. Although respiratory symptoms may improve after recovery from an asthma exacerbation, the atelectatic lobe may not re-expand, resulting in repeated episodes of obstruction, infection, and inflammation that may eventually lead to bronchiectasis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/20-23\">",
"       20-23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34903?source=see_link&amp;anchor=H3#H3\">",
"       \"Atelectasis in children\", section on 'Obstructive atelectasis'",
"      </a>",
"      .) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64077 \" href=\"UTD.htm?3/38/3682\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Allergic bronchopulmonary aspergillosis, a pulmonary hypersensitivity reaction to Aspergillus fumigatus, causes intense chronic airway inflammation. Repeated episodes of inflammation, mucoid impaction, and bronchial obstruction can lead to central bronchiectasis, fibrosis, and respiratory compromise (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64077 \" href=\"UTD.htm?3/38/3682\">",
"       image 2",
"      </a>",
"      ). This disorder typically occurs in patients with asthma and cystic fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link\">",
"       \"Allergic bronchopulmonary aspergillosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchocentric granulomatosis is a destructive, granulomatous lesion of the bronchi and bronchioles that is generally believed to represent a nonspecific response to a variety of types of airway injury. Approximately half of all cases are associated with asthma and allergic bronchopulmonary aspergillosis (ABPA). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44484?source=see_link\">",
"       \"Bronchocentric granulomatosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Other causes of airway obstruction that can result in bronchiectasis in the pediatric population include granulomatous diseases of the airway (eg, tuberculosis) and lymph node enlargement [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/10\">",
"       10",
"      </a>",
"      ]. Airway tumors are rare in children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"       \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15672738\">",
"    <span class=\"h2\">",
"     Immunodeficiency states",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital and acquired immunodeficiency disorders predispose the host to recurrent infections and to the development of bronchiectasis, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link\">",
"       \"Natural history and classification of pediatric HIV infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      X-linked agammaglobulinemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21321?source=see_link\">",
"       \"Agammaglobulinemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      IgG subclass deficiencies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"       \"Primary humoral immune deficiencies: An overview\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Common variable immunodeficiency (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=see_link\">",
"       \"Common variable immunodeficiency in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      DiGeorge syndrome (thymus hypoplasia) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15608?source=see_link\">",
"       \"DiGeorge syndrome: Management and prognosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Severe combined immunodeficiency (SCID) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"       \"Severe combined immunodeficiency (SCID): An overview\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other combined immunodeficiencies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link\">",
"       \"Combined immunodeficiencies\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Complement deficiencies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"       \"Inherited disorders of the complement system\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chronic granulomatous disease (CGD) and other disorders causing leukocyte dysfunction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"       \"Primary disorders of phagocytic function: An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=see_link\">",
"       \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Major histocompatibility complex (MHC, also known as HLA) deficiencies cause bare lymphocyte syndrome, which is often associated with mutations in the",
"      <strong>",
"       T",
"      </strong>",
"      ransporter associated with",
"      <strong>",
"       A",
"      </strong>",
"      ntigen",
"      <strong>",
"       P",
"      </strong>",
"      resentation (TAP) gene [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28329?source=see_link\">",
"       \"CD3/T cell receptor complex disorders causing immunodeficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The type of pulmonary infection varies depending on the nature of the immunodeficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bronchiectasis has occasionally been reported in patients with selective IgA deficiency, which is the most common immune deficiency disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/31\">",
"     31",
"    </a>",
"    ]. However, it is not clear whether this is a true association. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=see_link&amp;anchor=H16#H16\">",
"     \"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis\", section on 'Sinopulmonary'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Abnormal secretion clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders in which clearance of secretions from the airways is impaired predispose to recurrent pulmonary infection and thus to bronchiectasis. Because these disorders usually affect the entire airway, the infection and bronchiectasis tend to be diffusely distributed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cystic fibrosis (CF) is the most common cause of bronchiectasis in industrialized countries; it is a less predominant cause in developing nations or indigenous populations, in which infectious causes of bronchiectasis are more common [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/10\">",
"       10",
"      </a>",
"      ]. Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in abnormal ion and water transport across the respiratory epithelial cell, resulting in thick, desiccated mucus. Airway obstruction with mucus and poor mucociliary clearance allows bacterial infection to occur, causing inflammation and subsequent airway damage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary ciliary dyskinesia (PCD) is a disorder of ciliary function due to ultrastructural defects of the cilium (most commonly the outer dynein arms). Half of the patients with PCD have situs inversus (Kartagener syndrome). Children typically present with recurrent sinusitis, otitis media, and recurrent pneumonia due to impaired ciliary function, and bronchiectasis ultimately occurs in most of these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9817?source=see_link\">",
"       \"Primary ciliary dyskinesia (immotile-cilia syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Young's syndrome is characterized by obstructive azoospermia and sinopulmonary infections, but no identifiable ciliary dysfunction or structural defect [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/33\">",
"       33",
"      </a>",
"      ]. Mucociliary clearance is impaired, and bronchiectasis has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/34\">",
"       34",
"      </a>",
"      ]. Some cases may have been caused by mercury exposure during childhood; other reported cases of Young's syndrome may be atypical variants of CF or PCD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations and diagnosis of bronchiectasis in adults\", section on 'Young's syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with muscular dystrophies and other diseases with neuromuscular weakness often have impaired mucus clearance, due to ineffective cough and chest wall deformities, which can lead to recurrent pulmonary infection and bronchiectasis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"       \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developing nations and some indigenous populations, chronic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    undertreated pulmonary infection remains a common cause of bronchiectasis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/1,10,20\">",
"     1,10,20",
"    </a>",
"    ]. In most populations in industrialized nations, infection is an uncommon cause of bronchiectasis unless there is an underlying anatomic or immunologic defect.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent bacterial bronchitis (PBB) is increasingly recognized as a cause of chronic wet cough, particularly in young children. Identification and treatment of PBB is important because it may be a precursor to chronic suppurative lung disease, including bronchiectasis. In some indigenous populations, PBB may be an important cause of bronchiectasis previously thought to be \"idiopathic\" [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. However, the prevalence of PBB and association with bronchiectasis is difficult to establish, because the bacterial infection is rarely confirmed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28088?source=see_link&amp;anchor=H4#H4\">",
"       \"Causes of chronic cough in children\", section on 'Persistent bacterial bronchitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumonia &mdash; Bacterial pneumonia occasionally leads to bronchiectasis, particularly if recurrent or associated with an underlying anatomic or immune defect. Mycoplasma pneumonia usually has a benign course. However, in a series of 38 children hospitalized with mycoplasma pneumonia, eight were found to have bronchiectasis when evaluated with high resolution CT (HRCT) scan after long-term follow up [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link&amp;anchor=H13#H13\">",
"       \"Mycoplasma pneumoniae infection in children\", section on 'Radiographic features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Childhood infections with pertussis and measles have been associated with the development of bronchiectasis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. In a series of children with bronchiectasis diagnosed between 1946 and 1955, bronchiectasis was frequently preceded by an infection with pertussis (21 percent) or measles (14 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/39\">",
"       39",
"      </a>",
"      ]. However, since the advent of routine vaccinations, the incidence of these childhood infections has markedly decreased. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical presentation and diagnosis of measles\", section on 'Complications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link\">",
"       \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adenovirus infection, especially the type 7 strain, has been associated with bronchiectasis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/41\">",
"       41",
"      </a>",
"      ] and abnormal lung function [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/42\">",
"       42",
"      </a>",
"      ]. In addition, adenovirus has been associated with the development of Swyer James syndrome, which is characterized by unilateral small hyperlucent lung with bronchiectasis and diminished arterial supply [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/43\">",
"       43",
"      </a>",
"      ]. Swyer James syndrome has also been associated with other viral infections, pertussis, foreign body and hydrocarbon ingestion [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/43-45\">",
"       43-45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/11/44214?source=see_link&amp;anchor=H8#H8\">",
"       \"Congenital lobar emphysema\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mycobacterial infection &mdash; Tuberculosis remains an important cause of bronchiectasis in children from endemic countries and in children with HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/6,20\">",
"       6,20",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=see_link\">",
"       \"Tuberculosis disease in children\"",
"      </a>",
"      ). Mycobacterium avium-intracellulare complex (MAC), an opportunistic infection usually associated with immunodeficiencies such as HIV infection, results in lung pathology including adenopathy, cavitation, and bronchiectasis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38777?source=see_link\">",
"       \"Mycobacterium avium complex (MAC) infections in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recurrent aspiration &mdash; Chronic aspiration of gastric contents or secretions may occur in patients with neurologic disease and in congenital disorders, such as tracheoesophageal fistula [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/46-48\">",
"       46-48",
"      </a>",
"      ]. This may result in a variety of respiratory symptoms and diseases, including apnea, laryngospasm, chronic cough, asthma, pneumonia, and bronchiectasis. In children without neurologic dysfunction or anatomic abnormalities, gastroesophageal reflux disease (GERD) appears to be associated with a modestly increased risk of bronchiectasis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/46\">",
"       46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38632?source=see_link\">",
"       \"Aspiration due to swallowing dysfunction in infants and children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link&amp;anchor=H22#H22\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\", section on 'Recurrent pneumonia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other disorders",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchiolitis obliterans describes a pattern of histologic abnormalities affecting the small airways. It is a common complication of chronic rejection of lung transplantation, due to chronic rejection. It also may be seen in the context of bone marrow transplantation, interstitial lung disease, or as a post-infectious process. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"       \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Connective tissue disorders, particularly systemic lupus erythematosus (SLE), can be complicated by bronchiectasis. More than half of adult patients with SLE have thoracic involvement, which may include primary disease, such as alveolitis or interstitial lung disease (ie, bronchiolitis obliterans with organizing pneumonia), or atelectasis caused by diaphragmatic dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/13,49\">",
"       13,49",
"      </a>",
"      ]. In one series, bronchiectasis was detected by HRCT scan in 21 percent of adult patients with SLE [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/50\">",
"       50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42534?source=see_link\">",
"       \"Pulmonary manifestations of systemic lupus erythematosus in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that is typically first diagnosed during adolescence or young adulthood. The disease often causes granulomatous inflammation of the bronchial mucosa, peribronchial, perivascular, and subpleural areas of the lung [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/13\">",
"       13",
"      </a>",
"      ]. Mild bronchiectasis has been described in an adolescent with sarcoidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/51\">",
"       51",
"      </a>",
"      ]. Bronchoscopy and bronchography in adult patients with sarcoidosis suggest that bronchiectasis may be caused by airway wall destruction and weakening by granulomas, or by distortion of the airway by pulmonary fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Marfan syndrome is an inherited abnormality of connective tissue. In a case series of 100 patients with Marfan syndrome, five had pneumonia, three had history of frequent lower respiratory tract illness, and two had bronchiectasis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/53\">",
"       53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"       \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammatory bowel disease (IBD) is frequently associated with extra-intestinal involvement, including joints, skin, and eyes [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/54\">",
"       54",
"      </a>",
"      ]. Rarely, pulmonary disease may occur, including airway inflammation and parenchymal disease. Subglottic stenosis, chronic bronchitis associated with bronchiectasis, and interstitial lung disease including bronchiolitis obliterans with organizing pneumonia have been observed [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/55\">",
"       55",
"      </a>",
"      ]. Among children with IBD, bronchiectasis is rare but has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16057/abstract/56\">",
"       56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29034?source=see_link\">",
"       \"Pulmonary complications of inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/57/40850?source=see_link\">",
"       \"Patient information: Bronchiectasis in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchiectasis is characterized by abnormal dilation and distortion of the bronchial tree, resulting in chronic obstructive lung disease. This condition is the end result of a variety of pathophysiologic processes, usually including some combination of infection and impaired mucus drainage or airway obstruction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In developed nations, cystic fibrosis (CF) is the most common cause of bronchiectasis in children. The evaluation and management of CF-related bronchiectasis is discussed in detail in separate topic reviews. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The prevalence of non-CF related bronchiectasis in most populations in developed nations is low. However, some indigenous populations have prevalence rates of as high as 15 per 1000 children. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non CF-related bronchiectasis can be caused by a variety of pathogenic processes (",
"      <a class=\"graphic graphic_table graphicRef87712 \" href=\"UTD.htm?26/62/27630\">",
"       table 2",
"      </a>",
"      ). In children, important or common causes of bronchiectasis include: &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Immunodeficiency states (eg, agammaglobulinemia or IgG subclass deficiencies, or common variable immunodeficiency). (See",
"      <a class=\"local\" href=\"#H15672738\">",
"       'Immunodeficiency states'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"       \"Approach to the child with recurrent infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary ciliary dyskinesia. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Abnormal secretion clearance'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9817?source=see_link\">",
"       \"Primary ciliary dyskinesia (immotile-cilia syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infections such as persistent bacterial bronchitis, recurrent pneumonia, adenovirus or other childhood viral illnesses. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Foreign body aspiration. Bronchiectasis associated with foreign body aspiration is usually focal or localized. (See",
"      <a class=\"local\" href=\"#H2793993\">",
"       'Acquired bronchial obstruction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"       \"Airway foreign bodies in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital anomalies of the intrathoracic airways. (See",
"      <a class=\"local\" href=\"#H2794234\">",
"       'Bronchial narrowing or obstruction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchiolitis obliterans (most commonly seen as a complication of lung transplantation).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The causes of bronchiectasis can also be categorized by their characteristic distribution (eg, focal versus generalized) (",
"      <a class=\"graphic graphic_table graphicRef71732 \" href=\"UTD.htm?11/39/11900\">",
"       table 1",
"      </a>",
"      ). This categorization can be helpful in targeting the evaluation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Causes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44662?source=see_link\">",
"       \"Clinical manifestations and evaluation of bronchiectasis in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/1\">",
"      Kumar NA, Nguyen B, Maki D. Bronchiectasis: current clinical and imaging concepts. Semin Roentgenol 2001; 36:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/2\">",
"      Marwah OS, Sharma OP. Bronchiectasis. How to identify, treat, and prevent. Postgrad Med 1995; 97:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/3\">",
"      Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic costs of bronchiectasis. American Thoracic Society International Conference, May 21&ndash;26 2004, Orlando, Florida, USA. Amer J Resp Crit Care Med 2004; 169 (7 supplement):330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/4\">",
"      Waite DA, Wakefield SJ, Mackay JB, Ross IT. Mucociliary transport and ultrastructural abnormalities in Polynesian bronchiectasis. Chest 1981; 80:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/5\">",
"      Chang AB, Grimwood K, Mulholland EK, et al. Bronchiectasis in indigenous children in remote Australian communities. Med J Aust 2002; 177:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/6\">",
"      Singleton R, Morris A, Redding G, et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol 2000; 29:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/7\">",
"      Munro KA, Reed PW, Joyce H, et al. Do New Zealand children with non-cystic fibrosis bronchiectasis show disease progression? Pediatr Pulmonol 2011; 46:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/8\">",
"      Osika E, Cavaillon JM, Chadelat K, et al. Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. Eur Respir J 1999; 14:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/9\">",
"      Fiel, SB. Bronchiectasis: the changing clinical scenario. J Respir Dis 2000; 21:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/10\">",
"      Sethi GR, Batra V. Bronchiectasis: causes and management. Indian J Pediatr 2000; 67:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/11\">",
"      REID LM. Reduction in bronchial subdivision in bronchiectasis. Thorax 1950; 5:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/12\">",
"      Mysliwiec V, Pina JS. Bronchiectasis: the 'other' obstructive lung disease. Postgrad Med 1999; 106:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/13\">",
"      Cohen M, Sahn SA. Bronchiectasis in systemic diseases. Chest 1999; 116:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/14\">",
"      Gaillard EA, Carty H, Heaf D, Smyth RL. Reversible bronchial dilatation in children: comparison of serial high-resolution computer tomography scans of the lungs. Eur J Radiol 2003; 47:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/15\">",
"      Redding GJ. Bronchiectasis in children. Pediatr Clin North Am 2009; 56:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/16\">",
"      Javidan-Nejad C, Bhalla S. Bronchiectasis. Radiol Clin North Am 2009; 47:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/17\">",
"      Jones VF, Eid NS, Franco SM, et al. Familial congenital bronchiectasis: Williams-Campbell syndrome. Pediatr Pulmonol 1993; 16:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/18\">",
"      Rencken I, Patton WL, Brasch RC. Airway obstruction in pediatric patients. From croup to BOOP. Radiol Clin North Am 1998; 36:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/19\">",
"      Cataneo AJ, Reibscheid SM, Ruiz J&uacute;nior RL, Ferrari GF. Foreign body in the tracheobronchial tree. Clin Pediatr (Phila) 1997; 36:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/20\">",
"      Karakoc GB, Yilmaz M, Altintas DU, Kendirli SG. Bronchiectasis: still a problem. Pediatr Pulmonol 2001; 32:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/21\">",
"      De Boeck K, Willems T, Van Gysel D, et al. Outcome after right middle lobe syndrome. Chest 1995; 108:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/22\">",
"      Sekerel BE, Nakipoglu F. Middle lobe syndrome in children with asthma: review of 56 cases. J Asthma 2004; 41:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/23\">",
"      Priftis KN, Mermiri D, Papadopoulou A, et al. The role of timely intervention in middle lobe syndrome in children. Chest 2005; 128:2504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/24\">",
"      Eaton T, Garrett J, Milne D, et al. Allergic bronchopulmonary aspergillosis in the asthma clinic. A prospective evaluation of CT in the diagnostic algorithm. Chest 2000; 118:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/25\">",
"      Wark PA, Gibson PG. Allergic bronchopulmonary aspergillosis: new concepts of pathogenesis and treatment. Respirology 2001; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/26\">",
"      Sheikh S, Madiraju K, Steiner P, Rao M. Bronchiectasis in pediatric AIDS. Chest 1997; 112:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/27\">",
"      Pursner M, Haller JO, Berdon WE. Imaging features of Mycobacterium avium-intracellulare complex (MAC) in children with AIDS. Pediatr Radiol 2000; 30:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/28\">",
"      Gadola SD, Moins-Teisserenc HT, Trowsdale J, et al. TAP deficiency syndrome. Clin Exp Immunol 2000; 121:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/29\">",
"      Donato L, de la Salle H, Hanau D, et al. Association of HLA class I antigen deficiency related to a TAP2 gene mutation with familial bronchiectasis. J Pediatr 1995; 127:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/30\">",
"      Do��ru D, Ozba�� Ger&ccedil;eker F, Yal&ccedil;in E, et al. The role of TAP1 and TAP2 gene polymorphism in idiopathic bronchiectasis in children. Pediatr Pulmonol 2007; 42:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/31\">",
"      Buckley RH. Immunodeficiency diseases. JAMA 1992; 268:2797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/32\">",
"      Cowan MJ, Gladwin MT, Shelhamer JH. Disorders of ciliary motility. Am J Med Sci 2001; 321:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/33\">",
"      de Iongh R, Ing A, Rutland J. Mucociliary function, ciliary ultrastructure, and ciliary orientation in Young's syndrome. Thorax 1992; 47:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/34\">",
"      Neville E, Brewis R, Yeates WK, Burridge A. Respiratory tract disease and obstructive azoospermia. Thorax 1983; 38:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/35\">",
"      Hendry WF, A'Hern RP, Cole PJ. Was Young's syndrome caused by exposure to mercury in childhood? BMJ 1993; 307:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/36\">",
"      Arya AK, Beer HL, Benton J, et al. Does Young's syndrome exist? J Laryngol Otol 2009; 123:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/37\">",
"      Ichioka K, Kohei N, Okubo K, et al. Obstructive azoospermia associated with chronic sinopulmonary infection and situs inversus totalis. Urology 2006; 68:204.e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/38\">",
"      Kim CK, Chung CY, Kim JS, et al. Late abnormal findings on high-resolution computed tomography after Mycoplasma pneumonia. Pediatrics 2000; 105:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/39\">",
"      CLARK NS. Bronchiectasis in childhood. Br Med J 1963; 1:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/40\">",
"      Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/41\">",
"      Simil&auml; S, Linna O, Lanning P, et al. Chronic lung damage caused by adenovirus type 7: a ten-year follow-up study. Chest 1981; 80:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/42\">",
"      Sly PD, Soto-Quiros ME, Landau LI, et al. Factors predisposing to abnormal pulmonary function after adenovirus type 7 pneumonia. Arch Dis Child 1984; 59:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/43\">",
"      Daniel TL, Woodring JH, Vandiviere HM, Wilson HD. Swyer-James syndrome--unilateral hyperlucent lung syndrome. A case report and review. Clin Pediatr (Phila) 1984; 23:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/44\">",
"      Koll&eacute;e LA, van Heeswijk PJ, Schretlen ED. Unilateral hyperlucent lung with decreased vascular markings (Swyer-James syndrome). Padiatr Padol 1975; 10:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/45\">",
"      Kim CK, Koh JY, Han YS, et al. Swyer-James Syndrome with finger clubbing after severe measles infection. Pediatr Int 2008; 50:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/46\">",
"      El-Serag HB, Gilger M, Kuebeler M, Rabeneck L. Extraesophageal associations of gastroesophageal reflux disease in children without neurologic defects. Gastroenterology 2001; 121:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/47\">",
"      Pitney AC, Callahan CW, Ruess L. Reversal of bronchiectasis caused by chronic aspiration in cri du chat syndrome. Arch Dis Child 2001; 85:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/48\">",
"      Piccione JC, McPhail GL, Fenchel MC, et al. Bronchiectasis in chronic pulmonary aspiration: risk factors and clinical implications. Pediatr Pulmonol 2012; 47:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/49\">",
"      Kim JS, Lee KS, Koh EM, et al. Thoracic involvement of systemic lupus erythematosus: clinical, pathologic, and radiologic findings. J Comput Assist Tomogr 2000; 24:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/50\">",
"      Fenlon HM, Doran M, Sant SM, Breatnach E. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol 1996; 166:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/51\">",
"      Moffat RE, Sobonya RE, Chang CH. Childhood sarcoidosis with fatal cor pulmonale. Pediatr Radiol 1978; 7:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/52\">",
"      Udwadia ZF, Pilling JR, Jenkins PF, Harrison BD. Bronchoscopic and bronchographic findings in 12 patients with sarcoidosis and severe or progressive airways obstruction. Thorax 1990; 45:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/53\">",
"      Wood JR, Bellamy D, Child AH, Citron KM. Pulmonary disease in patients with Marfan syndrome. Thorax 1984; 39:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/54\">",
"      Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976; 55:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/55\">",
"      Camus P, Piard F, Ashcroft T, et al. The lung in inflammatory bowel disease. Medicine (Baltimore) 1993; 72:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16057/abstract/56\">",
"      T&uuml;rkta�� I, Bostanci I, Altunta�� B. Rapidly progressive bronchiectasis complicating ulcerative colitis in a child. Turk J Pediatr 2001; 43:151.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6358 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16057=[""].join("\n");
var outline_f15_43_16057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Congenital bronchiectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2794234\">",
"      Bronchial narrowing or obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2794249\">",
"      - Congenital airway or bronchial obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2793993\">",
"      - Acquired bronchial obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15672738\">",
"      Immunodeficiency states",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Abnormal secretion clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6358\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6358|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/34/35374\" title=\"algorithm 1\">",
"      Natural hx FBA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6358|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/31/8688\" title=\"diagnostic image 1\">",
"      Traction bronchiectasis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/38/3682\" title=\"diagnostic image 2\">",
"      Central bronchiectasis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6358|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/39/11900\" title=\"table 1\">",
"      Bronchiectasis by distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/62/27630\" title=\"table 2\">",
"      Causes and evaluation of bronchiectasis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21321?source=related_link\">",
"      Agammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38632?source=related_link\">",
"      Aspiration due to swallowing dysfunction in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34903?source=related_link\">",
"      Atelectasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44484?source=related_link\">",
"      Bronchocentric granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29144?source=related_link\">",
"      Bronchopulmonary sequestration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28329?source=related_link\">",
"      CD3/T cell receptor complex disorders causing immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28088?source=related_link\">",
"      Causes of chronic cough in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=related_link\">",
"      Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=related_link\">",
"      Clinical features and diagnosis of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44662?source=related_link\">",
"      Clinical manifestations and evaluation of bronchiectasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=related_link\">",
"      Clinical presentation and diagnosis of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=related_link\">",
"      Common variable immunodeficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/11/44214?source=related_link\">",
"      Congenital lobar emphysema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=related_link\">",
"      Congenital pulmonary airway (cystic adenomatoid) malformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=related_link\">",
"      Cystic fibrosis: Antibiotic therapy for lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15608?source=related_link\">",
"      DiGeorge syndrome: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/0/6150?source=related_link\">",
"      Management of bronchiectasis in children without cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38777?source=related_link\">",
"      Mycobacterium avium complex (MAC) infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=related_link\">",
"      Mycoplasma pneumoniae infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=related_link\">",
"      Natural history and classification of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/57/40850?source=related_link\">",
"      Patient information: Bronchiectasis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9817?source=related_link\">",
"      Primary ciliary dyskinesia (immotile-cilia syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29034?source=related_link\">",
"      Pulmonary complications of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42534?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=related_link\">",
"      Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18088?source=related_link\">",
"      Tracheomalacia and tracheobronchomalacia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=related_link\">",
"      Tuberculosis disease in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_43_16058="Clinical manifestations, diagnosis, and treatment of brucellosis";
var content_f15_43_16058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and treatment of brucellosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/43/16058/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16058/contributors\">",
"     Mile Bosilkovski, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/43/16058/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16058/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16058/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/43/16058/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/43/16058/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/43/16058/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brucellosis is a zoonotic infection transmitted to humans by contact with fluids from infected animals (sheep, cattle, goats, pigs, or other animals) or derived food products such as unpasteurized milk and cheese. It is one of the most widespread zoonoses worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/1\">",
"     1",
"    </a>",
"    ]. Brucellosis has high morbidity both for humans and animals; it is an important cause of economic loss and a public health problem in many developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of brucellosis will be reviewed here. The microbiology and epidemiology of the organism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33751?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of Brucella\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period is usually one to four weeks; occasionally, it may be as long as several months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. It is generally accepted that B. melitensis",
"    <sup>",
"    </sup>",
"    causes more severe infection than B. abortus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"    <sup>",
"     &nbsp;",
"    </sup>",
"    B. suis in humans can be as severe as B. melitensis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/7\">",
"     7",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    However, in a small series, patients infected with B. suis did not have a more severe clinical course compared to those infected with B. abortus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/8\">",
"     8",
"    </a>",
"    ]. B. canis is infrequently associated with human disease, and reported cases have usually been mild [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brucellosis is a systemic infection with a broad clinical spectrum, ranging from asymptomatic disease to severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fatal illness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/2\">",
"     2",
"    </a>",
"    ]. Clinical and laboratory features vary widely (",
"    <a class=\"graphic graphic_table graphicRef72072 \" href=\"UTD.htm?20/33/21021\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef59224 \" href=\"UTD.htm?19/1/19485\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/9\">",
"     9",
"    </a>",
"    ]. The main presentations are acute febrile illness with or without signs of localization, and chronic infection. Infection among children is generally more benign than in adults with respect to likelihood and severity of complications and response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brucellosis in pregnancy is associated with risk of spontaneous abortion, premature delivery, miscarriage, and intrauterine infection with fetal death [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brucellosis is not an opportunistic infection in patients infected with HIV or who have AIDS, even in areas of endemicity. Most patients with HIV infection and brucellosis have a benign clinical course in the early stages of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2043730\">",
"    <span class=\"h2\">",
"     Acute brucellosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute illness usually consists of the insidious onset of fever, night sweats (with a strong, peculiar, moldy odor), arthralgias, myalgias, low back pain, weight loss as well as weakness, fatigue, malaise, headache, dizziness, depression, and anorexia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/10,15,16\">",
"     10,15,16",
"    </a>",
"    ].",
"    <sup>",
"     &nbsp;",
"    </sup>",
"    A significant percentage of patients may have dyspepsia, abdominal pain, and cough. Physical findings are variable and nonspecific. Hepatomegaly, splenomegaly,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphadenopathy may be observed. The fever in untreated acute brucellosis can be high or slightly elevated and usually lasts for days to weeks. Irregular undulation has been described. Brucellosis can be a cause of fever of unknown origin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243133425\">",
"    <span class=\"h3\">",
"     Localized infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal infection occurs in about 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/2,17,18\">",
"     2,17,18",
"    </a>",
"    ]; brucellosis can affect any organ system [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoarticular involvement is the most common presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. The sacroiliac joints and large joints of the lower limbs are most frequently involved [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. Spondylitis is a serious complication of brucellosis; it is more prevalent in older patients and patients with prolonged illness prior to treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/19\">",
"       19",
"      </a>",
"      ]. The lumbar vertebrae are involved more frequently than the thoracic and cervical vertebrae. Paravertebral, epidural, and psoas abscess can occur in the setting of brucellar spondylitis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/22-24\">",
"       22-24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genitourinary involvement occurs in 2 to 20 percent of cases; orchitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      epididymitis are the most common manifestations. Less common manifestations include prostatitis, cystitis, interstitial nephritis, glomerulonephritis, and renal, testicular or tuboovarian abscess [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pulmonary involvement occurs in up to 7 percent of patients with brucellosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/26\">",
"       26",
"      </a>",
"      ]. Bronchitis, interstitial pneumonitis, lobar pneumonia, lung nodules, pleural effusion, hilar lymphadenopathy, empyema or abscesses may be observed [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/2,26,27\">",
"       2,26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gastrointestinal involvement can present with clinical hepatitis (3 to 6 percent of cases) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/16\">",
"       16",
"      </a>",
"      ]. Rarely, other manifestations include hepatic or splenic abscess, cholecystitis, pancreatitis, ileitis, colitis, and spontaneous peritonitis",
"     </li>",
"     <li>",
"      Hematological abnormalities, including anemia, leukopenia, thrombocytopenia, pancytopenia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      DIC, are relatively common [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/9,11\">",
"       9,11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neurological involvement occurs in 2 to 7 percent of cases. Manifestations include meningitis (acute or chronic), encephalitis, myelitis, radiculitis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neuritis (with involvement of cranial or peripheral nerves) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/3,11,16,25\">",
"       3,11,16,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac involvement is relatively rare but may include endocarditis, myocarditis, pericarditis, endarteritis, thrombophlebitis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mycotic aneurysm of the aorta or ventricles. Of these, endocarditis occurs most frequently (1 to 2 percent of cases) and is the main cause of death attributable to brucellosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/2,3,11,16\">",
"       2,3,11,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ocular involvement most commonly presents with uveitis. Other manifestations include keratoconjunctivitis, corneal ulcers, iridocyclitis, nummular keratitis, choroiditis, optic neuritis,",
"      <sup>",
"      </sup>",
"      papilledema, and endophthalmitis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/28\">",
"       28",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Dermatologic manifestations occur in up to 10 percent of patients. Findings may include macular, maculopapular, scarlatiniform, papulonodular, and erythema nodosum-like eruptions, ulcerations, petechiae, purpura, granulomatous vasculitis, and abscesses [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/2,11,29\">",
"       2,11,29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2045094\">",
"    <span class=\"h2\">",
"     Relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of relapse following treatment is about 5 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/30\">",
"     30",
"    </a>",
"    ]. Relapse usually occurs within the first six months following completion of treatment, although it may occur up to twelve months following completion of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Causes of relapse include inadequate choice of antibiotics, shortened treatment duration, lack of adherence, or localized foci of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/19\">",
"     19",
"    </a>",
"    ]. Relapse due to antibiotic resistance is rare. In a multivariate model for predicting relapse, independent predictors included positive blood cultures at baseline, temperature of &ge;38.3",
"    <sup>",
"     0",
"    </sup>",
"    C, and duration of symptoms before treatment &lt;10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/34\">",
"     34",
"    </a>",
"    ]. In areas with ongoing exposure, clinical differentiation between relapse and reinfection can be difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/13,15,33\">",
"     13,15,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243133450\">",
"    <span class=\"h2\">",
"     Chronic brucellosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic brucellosis refers to patients with clinical manifestations for more than one year after the diagnosis of brucellosis is established [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/15,35\">",
"     15,35",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Chronic brucellosis is characterized by localized infection (generally spondylitis, osteomyelitis, tissue abscesses, or uveitis)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    relapse in patients with objective evidence of infection (elevated antibody titers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recovery of brucellae from blood or tissues).",
"   </p>",
"   <p>",
"    In some cases, patients attribute symptoms to chronic brucellosis in the absence of objective evidence for infection (low antibody titers, sterile cultures). Such patients typically have a cyclic course with intermittent back pain, arthralgias, sweats, and signs of psychoneurosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/15,16,35\">",
"     15,16,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory findings should be interpreted together with clinical manifestations, exposure history, occupation, and history of past infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Laboratory tools for diagnosis of brucellosis include culture, serology, and polymerase chain reaction (PCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/38\">",
"     38",
"    </a>",
"    ].",
"    <sup>",
"     &nbsp;",
"    </sup>",
"    Ideally, the diagnosis is made by culture of the organism from blood or other sites such as bone marrow or liver biopsy specimens. The sensitivity of culture is limited; if standard blood cultures are negative and brucellosis remains a consideration, the lab should be alerted regarding suspicion for brucellosis so that additional blood culture techniques can be performed. Serologic testing should also be performed; serum agglutination and ELISA are the most common serologic tests.",
"   </p>",
"   <p>",
"    Results of routine laboratory studies are usually nonspecific. White blood cell counts are usually normal to low; pancytopenia can occur. Minor abnormalities in hepatic enzymes are relatively common [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In neurobrucellosis, abnormalities of the cerebrospinal fluid typically include a pleocytosis of 10 to 200 white blood cells (predominantly mononuclear cells), elevated protein levels, and hypoglycorrhachia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/41\">",
"     41",
"    </a>",
"    ]. In the setting of findings consistent with aseptic meningitis, elevated levels of adenosine deaminase in cerebrospinal fluid suggest brucella meningitis (or tuberculous meningitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographs, bone scans, computerized tomography, magnetic resonance imaging, and echocardiography may be helpful in evaluating focal disease but do not provide a definitive diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of brucellosis is established when Brucella are isolated from blood, bone marrow, or other body fluids or tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/15\">",
"     15",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Culture techniques are time consuming, insensitive and pose risk for laboratory infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/3\">",
"     3",
"    </a>",
"    ]. The classic biphasic (solid and liquid) Ruiz-Castaneda blood culture technique is still used in developing settings but automated blood culture systems are more effective [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/10\">",
"     10",
"    </a>",
"    ]. The percentage of cases with positive blood cultures ranges from 15 to 70",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/10\">",
"     10",
"    </a>",
"    ].",
"    <sup>",
"     &nbsp;",
"    </sup>",
"    The majority of blood cultures are positive between the 7th and 21st day [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/43\">",
"     43",
"    </a>",
"    ]. The semiautomatic methods (BACTEC 9204 and",
"    <span class=\"nowrap\">",
"     Bac/Alert)",
"    </span>",
"    shorten considerably the time taken for detection; the presence of Brucella can be detected by the third day of incubation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/7,15,44\">",
"     7,15,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lysis-centrifugation technique provides rapid diagnosis and also has high sensitivity in confirmation of brucellosis, especially of chronic illness. In one report, the lysis-centrifugation technique was more sensitive than Ruiz-Castaneda culture in both acute (91 versus 72 percent) and chronic brucellosis (74 versus 33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/45\">",
"     45",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Compared with early versions of automated blood culture systems, the lysis-centrifugation approach had shorter time to detection, but in some cases, the automated systems produced higher sensitivity rates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/46\">",
"     46",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Studies with the newer continuous monitoring systems indicate that the BACTEC 9000 series is able to achieve times to detection that are shorter than those of lysis-centrifugation and has greater sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/47\">",
"     47",
"    </a>",
"    ].",
"    <sup>",
"     &nbsp;",
"    </sup>",
"   </p>",
"   <p>",
"    Bone marrow culture is considered the gold standard for the diagnosis of brucellosis. It is significantly more sensitive than blood culture, especially in chronic cases. The time to detection is shorter, and prior use of antibiotics does not reduce the sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/48\">",
"     48",
"    </a>",
"    ].",
"    <sup>",
"     &nbsp;",
"    </sup>",
"    However, because harvesting bone marrow for culture is an invasive procedure, bone marrow culture is reserved for patients with abnormal hematologic findings, fever of unknown origin, and negative brucellosis serology [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Serologic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A presumptive diagnosis of brucellosis can be made by demonstrating elevated or rising titers of specific serum antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/15\">",
"     15",
"    </a>",
"    ].",
"    <sup>",
"     &nbsp;",
"    </sup>",
"    The interpretation of serological tests can be difficult, particularly in the setting of chronic infection, reinfection, relapse, and in endemic areas where a high proportion of the population has antibodies against brucellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/27\">",
"     27",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Positive serological tests results can persist long after recovery in treated individuals, so it is not always possible to distinguish serologically between active and past infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/36,37,49\">",
"     36,37,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of serologic methods that allow the detection of antibodies against the cell wall components or some cytoplasmic proteins have been used:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum agglutination (standard tube agglutination)",
"     </li>",
"     <li>",
"      ELISA (enzyme-linked immunosorbent assay)",
"     </li>",
"     <li>",
"      Rose Bengal agglutination",
"     </li>",
"     <li>",
"      Coombs test",
"     </li>",
"     <li>",
"      Immunocapture agglutination (Brucellacapt)",
"     </li>",
"     <li>",
"      2-mercaptoethanol agglutination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum agglutination testing (SAT) is the modality for which there is the greatest published experience and remains the reference to which other tests are compared [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/3,15,50\">",
"     3,15,50",
"    </a>",
"    ]. The best serological definition of brucellosis is confirmation by a fourfold or greater rise in Brucella agglutination titer between acute- and convalescent-phase serum specimens obtained &ge;2 weeks apart and studied at the same laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/51\">",
"     51",
"    </a>",
"    ], but often this definition is not clinically practical and may delay therapy. There are no absolute thresholds for confirmatory titers. In general, positive titers consist of 1:80 in nonendemic regions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/36\">",
"     36",
"    </a>",
"    ] and 1:160 in endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/17,18,31\">",
"     17,18,31",
"    </a>",
"    ].",
"    <sup>",
"     &nbsp;",
"    </sup>",
"    It is important to note that infection with B. canis does not produce antibodies that cross-react with standard Brucella antigens. B. canis serology should be specifically requested if illness due to this species is suspected, or if brucellosis is suspected but the standard tube agglutination test is negative [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/44,52\">",
"     44,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ELISA is the second most common serologic method utilized in evaluating patients with suspected Brucella infections. ELISA is rapid, objective, highly sensitive and specific; it measures IgM, IgG, and IgA [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/44\">",
"     44",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    While ELISA with S-LPS is a very promising test, there are problems of inter-laboratory comparability due to issues related to standardization, reagent quality and interpretation of results (particularly when based on optical density readings alone); standard reference materials are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/7,15,36\">",
"     7,15,36",
"    </a>",
"    ]. One investigation concluded that ELISA did not improve diagnostic accuracy compared to SAT and Coombs in combination [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/53\">",
"     53",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Another showed that the sensitivity of either ELISA IgM or IgG were lower than SAT; the sensitivity and specificity were similar when IgM and IgG were used in combination [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/54\">",
"     54",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Diagnostic use of ELISA anti-LPS and anti-cytoplasmic protein antibodies appears to be helpful in combination [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rose Bengal plate agglutination test is often used as a rapid screening test, with very high sensitivity (&gt;99 percent), and fairly high specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/53\">",
"     53",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"   </p>",
"   <p>",
"    The Coombs and immunocapture agglutination (Brucellacapt) tests may be more suitable in relapsing brucellosis and patients with persistent active infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The 2-mercaptoethanol (2-ME) agglutination test measures IgG antibodies only, and is a good marker to follow disease activity after initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/15,27\">",
"     15,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a number of disadvantages associated with serologic tests. Cross-reactivity with other bacteria is a problem with standard tube agglutination; cross reacting organisms include Francisella tularensis, Yersinia enterocolitica O:9, Escherichia coli O116 and O157, Salmonella urbana, Vibrio cholerae, Xanthomonas maltophilia, and Afipia clevelandensis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/10,56\">",
"     10,56",
"    </a>",
"    ]. False negative results are common early in the course of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/57\">",
"     57",
"    </a>",
"    ], in the setting of immunosuppression and in the presence of incomplete or blocking antibodies (serum agglutination) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In addition, a &lsquo;prozone&rsquo; phenomenon may also be observed with serum agglutination testing (eg, inhibition of agglutination at low dilutions due to an excess of antibodies or to non-specific serum factors) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/15,56\">",
"     15,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Molecular tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) is a promising tool for rapid and accurate diagnosis of human brucellosis. PCR can be performed on blood or any body tissue and can yield positive results as early as 10 days after inoculation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/10\">",
"     10",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    PCR-based laboratory tests cannot yet be considered a routine diagnostic method, however, given the need for standardization of methods, infrastructure, equipment, expertise and a better understanding of the clinical significance of the results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/3,60\">",
"     3,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of molecular tests are available for the identification of Brucella to the genus and species levels; these are research tools. PCR assays targeting omp43, omp31, the 16S rRNA gene, 16S to 23S internal transcribed spacer regions, heat shock protein genes and the perosamine synthetase gene have been developed to detect Brucella species [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/61\">",
"     61",
"    </a>",
"    ]. All Brucella 16S rRNA gene sequences have been determined to be identical. Thus 16S, rRNA gene sequencing is useful for genus identification but cannot be used for species identification [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/62\">",
"     62",
"    </a>",
"    ]. Resolution to species level is possible through ribotyping, amplified fragment length polymorphism analysis, DNA sequencing of omp2 and omp25, and PCR assays targeting species-specific insertions of IS711 or IS650 elements [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22055922\">",
"    <span class=\"h2\">",
"     Synovial fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, analysis of synovial fluid (including cell count, glucose, protein, and culture) is not particularly helpful in the diagnosis of brucellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/63\">",
"     63",
"    </a>",
"    ]. In some circumstances, synovial fluid analysis may help distinguish Brucella arthritis from other causes. In the setting of Brucella arthritis, the synovial fluid white blood cell count does not generally exceed 15,000",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    which is similar to findings with reactive arthritis due to Salmonella and Yersinia species, but unlike the higher leukocyte count observed in other septic arthritides [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. In brucellosis, lymphocytes frequently predominate (in contrast to septic arthritis due to other bacteria, in which polymorphonuclear leukocytes frequently predominate) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22055929\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with spine symptoms should undergo MRI examination to rule out spinal cord compromise. Other useful modalities for evaluation of patients with suspected focal disease include plain radiographs, radionuclide bone scintigraphy, CT scanning, and joint sonography [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Localized snowflake calcification in chronic hepatosplenic brucellosis is the only specific radiographic finding that may be used to distinguish brucellosis from other diseases (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72028 \" href=\"UTD.htm?14/13/14546\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of brucellosis therapy is to control the illness and prevent complications, relapses, and sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Important principles of brucellosis treatment include use of antibiotics with activity in the acidic intracellular environment (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ), use of combination regimens, and prolonged duration of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/33,72\">",
"     33,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2045332\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Major regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major regimens for the treatment of adults with uncomplicated brucellosis (eg, not having spondylitis, neurobrucellosis, or endocarditis) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/30,73\">",
"     30,73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      100 mg orally twice daily for six weeks,",
"      <sup>",
"      </sup>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      1 g intramuscularly once daily for the first 14 to 21 days. It has been suggested that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      may be substituted for streptomycin; equal efficacy has been demonstrated [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/74\">",
"       74",
"      </a>",
"      ]. The optimal duration of gentamicin is uncertain; 5 days to 14 days is acceptable [",
"      <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      100 mg orally twice daily plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      600 to 900 mg (15",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      orally once daily. Both drugs are administered for six weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative efficacy of these regimens was evaluated in a randomized trial including 95 patients with brucellosis; patients with spondylitis were excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/75\">",
"     75",
"    </a>",
"    ]. The time to defervescence and the relapse rate at 12 months were comparable between the two regimens (3.2 versus 4.2 days, and 4.3 versus 4.9 percent, respectively). The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    regimen is considered the &ldquo;gold standard&rdquo; and has been proven to be more effective than doxycycline-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/30,76-78\">",
"     30,76-78",
"    </a>",
"    ]. In one meta-analysis, patients treated with doxycycline-streptomycin and doxycycline-rifampin regimen had successful cure in 92 and 81 percent of cases, respectively (p=0.0004) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/77\">",
"     77",
"    </a>",
"    ]. Another study comparing doxycycline-streptomycin and doxycycline-rifampin noted failure to respond to therapy in 7 versus 24 percent of patients, respectively (p=0.0016) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/76\">",
"     76",
"    </a>",
"    ]. However, many favor doxycycline-rifampin since it is relatively inexpensive and convenient [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/30,72\">",
"     30,72",
"    </a>",
"    ]. Streptomycin is not available in some regions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/30\">",
"     30",
"    </a>",
"    ], and parenteral aminoglycoside administration is not as convenient as oral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monotherapy and regimens shorter than six weeks are not accepted treatment strategies for brucellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/72,79\">",
"     72,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Alternative agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoroquinolones (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    500 mg twice daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    200 mg twice daily) have good in vitro activity against Brucella spp and can be used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , but are not appropriate first line agents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. They may be useful in the setting of drug resistance, antimicrobial toxicity, and some cases of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are some reports demonstrating more favorable cure rates with three-drug therapy than two-drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/83-87\">",
"     83-87",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX; one double-strength tablet twice a day) may be used as an additional (third) agent in complex cases of focal brucellosis, relapse, or refractory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/3,30,72\">",
"     3,30,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2045356\">",
"    <span class=\"h2\">",
"     Focal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, longer courses of therapy (at least 12 weeks) are warranted for treatment of spondylitis, neurobrucellosis, endocarditis, or localized suppurative lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/79\">",
"     79",
"    </a>",
"    ]. At least three drugs are generally warranted in the setting of neurobrucellosis, endocarditis, and localized suppurative lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/3\">",
"     3",
"    </a>",
"    ]. In general, other forms of localized infection are treated in the same way as uncomplicated brucellosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243133482\">",
"    <span class=\"h3\">",
"     Spondylitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for Brucella spondylitis should consist of two antibiotic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/22,88\">",
"     22,88",
"    </a>",
"    ] for at least 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/22,72,88-90\">",
"     22,72,88-90",
"    </a>",
"    ]. Patients with Brucella spondylitis appear to respond better to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg orally twice daily for 12 weeks) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    (1 g intramuscularly once daily for the first 14 to 21 days) than to doxycycline-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/88\">",
"     88",
"    </a>",
"    ]. Alternative choices include doxycycline (100 mg orally twice daily) plus rifampin (600 to 900 mg (15",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    once daily) for at least 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/22,88\">",
"     22,88",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 mg twice daily) plus rifampin for at least 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of therapy is at least as important as the choice of antimicrobial agents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/90\">",
"     90",
"    </a>",
"    ]. In one meta-analysis, the failure rate for patients treated less than six weeks was 43 percent; the failure rate for patients treated more than twelve weeks was 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgery may be warranted in the setting of spinal instability, persistence or progression of neurological deficit, vertebral collapse, or localized abscess (epidural or paravertebral) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/2,33\">",
"     2,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1706658799\">",
"    <span class=\"h3\">",
"     Neurobrucellosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most experts favor administration of two or three drugs that cross the blood-brain-CSF barrier for treatment of neurobrucellosis. Reasonable regimens include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/11,91,92\">",
"     11,91,92",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/3,33\">",
"     3,33",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Ceftriaxone-based regimens may be more successful and allow shorter duration of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/93\">",
"     93",
"    </a>",
"    ]. The duration of therapy is generally prolonged (months) and needs to be individualized according to clinical signs and symptoms; in general it should be continued until cerebrospinal fluid parameters have returned to normal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of corticosteroids is uncertain and they are not part of routine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/94\">",
"     94",
"    </a>",
"    ]. Use of steroids may be appropriate in the setting of neurobrucellosis complicated by iritis, papilledema, myelopathy, polyneuropathy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cranial nerve palsies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1706658805\">",
"    <span class=\"h3\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocarditis is rare but life-threatening complication of brucellosis. Most patients with endocarditis due to brucellosis require a combination of surgery and antimicrobial agents for the best chance of cure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/7\">",
"     7",
"    </a>",
"    ], although a small number of cases treated successfully with antimicrobial therapy alone have been reported. Antimicrobial therapy alone may be attempted in the absence of heart failure, valvular destruction, abscess, or a prosthetic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/96\">",
"     96",
"    </a>",
"    ]. The approach to therapy is largely based upon small series and case reports.",
"   </p>",
"   <p>",
"    A combination of antimicrobials should be used; the optimal combination is uncertain but data suggest mortality may be lower when the treatment regimen includes an aminoglycoside [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/97\">",
"     97",
"    </a>",
"    ]. In general thus far, clinical experience has been best using combination therapy with an aminoglycoside,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ; further study is needed.",
"   </p>",
"   <p>",
"    The optimal duration of therapy is uncertain; therapy is usually given for six weeks to six months (mean duration three months) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/3,96\">",
"     3,96",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Following valve replacement the duration of antimicrobial therapy is also uncertain; the decision to stop treatment must be determined on an individual basis after thorough clinical observation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1706658861\">",
"    <span class=\"h2\">",
"     Relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse should prompt assessment for a focal lesion. While antimicrobial susceptibility should be performed on any culture isolate, development of resistance is rare. Most relapses can be treated successfully with a repeat course of a standard regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/10,19,30,31,33\">",
"     10,19,30,31,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occurrence of second or third relapse should prompt selection of an alternative regimen (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Alternative agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2045448\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of brucellosis in pregnant women is a challenging problem with limited data. Regimens include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (900 mg once daily), with or without TMP SMX (one double-strength tablet twice a day) for six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/3,33,79\">",
"     3,33,79",
"    </a>",
"    ]. Use of TMP-SMX during the last week prior to delivery is associated with kernicterus and should be avoided if possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment recommendations for children are based upon studies in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/74,75,98\">",
"     74,75,98",
"    </a>",
"    ], observational data [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/87,99-102\">",
"     87,99-102",
"    </a>",
"    ], and a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/103\">",
"     103",
"    </a>",
"    ]. Combination therapy with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (for children &ge;8 years) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX, for children &lt;8 years) and at least one other agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    , depending upon the site of the infection) decreases the rate of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/102,104\">",
"     102,104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics (AAP) suggests that children who do not have osteoarticular disease, neurobrucellosis, or endocarditis be treated as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/102,104-107\">",
"     102,104-107",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &lt;8 years of age &mdash; Oral TMP-SMX plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      for four to six weeks.",
"     </li>",
"     <li>",
"      &ge;8 years of age &mdash; Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      agent (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      or tetracycline) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      for six weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with osteoarticular disease, neurobrucellosis, or endocarditis should be treated for at least six weeks (and up to six months for life-threatening infection) as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/104,108-110\">",
"     104,108-110",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &lt;8 years of age &mdash; Oral TMP-SMX for at least six weeks plus parenteral aminoglycoside (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      ) for the first 14 days of therapy.",
"     </li>",
"     <li>",
"      &ge;8 years of age &mdash; Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      agent (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      or tetracycline) for at least six weeks plus parenteral aminoglycoside (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      ) for the first 14 days of therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    may be added to the regimens above to decrease the risk of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doses for the antimicrobial agents are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/102-104,109\">",
"     102-104,109",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TMP-SMX (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day TMP [maximum 480",
"      <span class=\"nowrap\">",
"       mg/day]",
"      </span>",
"      and 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day SMX [maximum 2.4",
"      <span class=\"nowrap\">",
"       g/day]",
"      </span>",
"      by mouth divided in two doses).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (2 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day by mouth [maximum 200",
"      <span class=\"nowrap\">",
"       mg/day]",
"      </span>",
"      divided in two doses).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       Tetracycline",
"      </a>",
"      (30 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day by mouth [maximum 2",
"      <span class=\"nowrap\">",
"       g/day]",
"      </span>",
"      divided in four doses).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      (15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day by mouth [maximum 900",
"      <span class=\"nowrap\">",
"       mg/day]",
"      </span>",
"      divided in one or two doses).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       Gentamicin",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day parenterally divided in one to three doses).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       Streptomycin",
"      </a>",
"      (20 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day [maximum dose 1",
"      <span class=\"nowrap\">",
"       g/day]",
"      </span>",
"      parenterally divided in two doses) for the first 14 days of therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     Gentamicin",
"    </a>",
"    has been primarily evaluated in children in whom a short course (five days at 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) has been used in combination with another drug [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22057110\">",
"    <span class=\"h2\">",
"     Post exposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-risk exposure in a microbiology laboratory warrants baseline serologic testing and post-exposure prophylaxis (PEP) as outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef60500 \" href=\"UTD.htm?40/49/41756\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/111\">",
"     111",
"    </a>",
"    ]. Management of brucella vaccine accidents warrants baseline serologic testing and a full treatment course of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/15,33\">",
"     15,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2045253\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfavorable outcomes (defined by relapses and therapeutic failures) are usually a result of failure to eradicate intracellular bacteria. Therapeutic failures are usually associated with brucellar spondylitis and have been reported in up to 15 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/9\">",
"     9",
"    </a>",
"    ].",
"    <sup>",
"     &nbsp;",
"    </sup>",
"    Rarely, moderate to severe sequelae occur in the setting of spondylitis and neurobrucellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/22,24,94\">",
"     22,24,94",
"    </a>",
"    ]. The prognosis of neurobrucellosis is variable; in one report of 18 patients, 11 showed complete recovery of neurologic function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/94\">",
"     94",
"    </a>",
"    ]. With appropriate antimicrobial treatment, the mortality rate of brucellosis is &lt;1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/2,9,17\">",
"     2,9,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brucellosis may be prevented via vaccination of domestic livestock, serologic testing, quarantine of herds, and slaughter of infected animals. Vaccination is effective for cattle (B. abortus strain 19 and RB51), sheep, and goats (B. melitensis Rev-1), but requires a sustained vaccination program over several years. These are live attenuated vaccines that are also known to cause disease in humans during the process of preparation or by accidental inoculation; inadvertent exposure requires careful followup [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/7,15,51,112\">",
"     7,15,51,112",
"    </a>",
"    ]. No vaccine is available for protecting swine against B. suis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22057110\">",
"     'Post exposure prophylaxis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Protection of slaughterhouse workers includes separation of the killing floor from other processing areas, using designated slaughter houses for known infected animals, use of protective clothing and disinfectants, and control of air circulation. Pasteurization of milk is also very important for the prevention of transmission to humans [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaccination for the prevention of human brucellosis is not available [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/3,7\">",
"     3,7",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Improved understanding of disease pathogenesis may allow for identification of possible vaccine targets in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?15/43/16058/abstract/10,113-115\">",
"     10,113-115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical manifestations of brucellosis include fever, night sweats, malaise, anorexia, arthralgias, fatigue, weight loss, and depression. Patients may have a multitude of complaints with fever in the absence of other objective findings. The onset of symptoms may be abrupt or insidious, developing over several days to weeks. The musculoskeletal and genitourinary systems are the most common sites of involvement. Neurobrucellosis, endocarditis, and hepatic abscess occur in 1 to 2 percent of cases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of brucellosis should be considered in an individual with otherwise unexplained fever and nonspecific complaints who has a possible source of exposure (eg, contact with animal tissues, ingestion of unpasteurized milk or cheese). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory tools for diagnosis of brucellosis include culture and serology. Ideally, the diagnosis is made by culture of the organism from blood or other sites, such as bone marrow or liver biopsy specimens. Serologic tests include tube agglutination and enzyme-linked immunosorbent assay (ELISA). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adults with non-focal disease, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Dosing is doxycycline 100 mg orally twice daily plus rifampin 600 to 900 mg (15",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      orally once daily for six weeks. (See",
"      <a class=\"local\" href=\"#H2045332\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adults with spondylitis, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Dosing is doxycycline 100 mg orally twice daily for at least 12 weeks, plus streptomycin 1 gram intramuscularly once daily for the first 14 to 21 days. (See",
"      <a class=\"local\" href=\"#H243133482\">",
"       'Spondylitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adults with neurobrucellosis, we suggest treatment with two or three drugs that cross the blood-brain barrier such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The duration of therapy is generally prolonged and needs to be individualized according to clinical signs and symptoms; in general, it should be continued until cerebrospinal fluid parameters have returned to normal. (See",
"      <a class=\"local\" href=\"#H1706658799\">",
"       'Neurobrucellosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most adults with Brucella endocarditis require valve replacement together with a prolonged course of antimicrobial therapy. We suggest a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , and an aminoglycoside (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1706658805\">",
"       'Endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnant patients, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The approach to treatment of children is outlined above. (See",
"      <a class=\"local\" href=\"#H2045448\">",
"       'Pregnant women'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Children'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Brucellosis may be prevented via vaccination, which is effective for cattle, sheep, and goats, but requires a sustained vaccination program over several years. Other measures include the quarantine of herds and the slaughter of infected animals (with protective measures in slaughterhouses). Pasteurization of milk is also very important for the prevention of transmission to humans. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/1\">",
"      Bosilkovski M, Dimzova M, Grozdanovski K. Natural history of brucellosis in an endemic region in different time periods. Acta Clin Croat 2009; 48:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/2\">",
"      Colmenero JD, Reguera JM, Martos F, et al. Complications associated with Brucella melitensis infection: a study of 530 cases. Medicine (Baltimore) 1996; 75:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/3\">",
"      Mantur BG, Amarnath SK, Shinde RS. Review of clinical and laboratory features of human brucellosis. Indian J Med Microbiol 2007; 25:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/4\">",
"      Fiori PL, Mastrandrea S, Rappelli P, Cappuccinelli P. Brucella abortus infection acquired in microbiology laboratories. J Clin Microbiol 2000; 38:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/5\">",
"      Young EJ. An overview of human brucellosis. Clin Infect Dis 1995; 21:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/6\">",
"      Troy SB, Rickman LS, Davis CE. Brucellosis in San Diego: epidemiology and species-related differences in acute clinical presentations. Medicine (Baltimore) 2005; 84:174.",
"     </a>",
"    </li>",
"    <li>",
"     WHO/CDS/EPR/2006.7. Brucellosis in humans and animals Geneva: World Health Organization, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/8\">",
"      Buchanan TM, Faber LC, Feldman RA. Brucellosis in the United States, 1960-1972. An abattoir-associated disease. Part I. Clinical features and therapy. Medicine (Baltimore) 1974; 53:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/9\">",
"      Bosilkovski M, Krteva L, Dimzova M, et al. Human brucellosis in Macedonia - 10 years of clinical experience in endemic region. Croat Med J 2010; 51:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/10\">",
"      Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med 2005; 352:2325.",
"     </a>",
"    </li>",
"    <li>",
"     Doganay, M, Aygen, B. Human brucellosis: an overview. Int J Infect Dis 2003; 7:173.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/12\">",
"      Khan MY, Mah MW, Memish ZA. Brucellosis in pregnant women. Clin Infect Dis 2001; 32:1172.",
"     </a>",
"    </li>",
"    <li>",
"     Gotuzzo, E, Carillo, C. Brucella. In: Infectious Diseases (Third Edition), Gorbach, SL, Bartlett, JG, Blacklow, NR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. p.1717.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/14\">",
"      Moreno S, Ariza J, Espinosa FJ, et al. Brucellosis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1998; 17:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/15\">",
"      Young EJ. Brucellosis: current epidemiology, diagnosis, and management. Curr Clin Top Infect Dis 1995; 15:115.",
"     </a>",
"    </li>",
"    <li>",
"     Gotuzzo, E. Brucellosis. In: Tropical Infectious Diseases. Principles, Pathogens &amp; Practice, Guerrant, RL, Walker, DH, Weller, PF (Eds), Churchill Livingstone, Philadelphia 1999. p.498.",
"    </li>",
"    <li>",
"     Aygen, B, Doganay, M, Sumerkan, B, et al. Clinical manifestations, complications and treatment of brucellosis: a retrospective evaluation of 480 patients. Med Malad Infect 2002; 32:485.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/18\">",
"      Hasanjani Roushan MR, Mohrez M, Smailnejad Gangi SM, et al. Epidemiological features and clinical manifestations in 469 adult patients with brucellosis in Babol, Northern Iran. Epidemiol Infect 2004; 132:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/19\">",
"      Bosilkovski M, Krteva L, Caparoska S, Dimzova M. Osteoarticular involvement in brucellosis: study of 196 cases in the Republic of Macedonia. Croat Med J 2004; 45:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/20\">",
"      Geyik MF, G&uuml;r A, Nas K, et al. Musculoskeletal involvement of brucellosis in different age groups: a study of 195 cases. Swiss Med Wkly 2002; 132:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/21\">",
"      Hashemi SH, Keramat F, Ranjbar M, et al. Osteoarticular complications of brucellosis in Hamedan, an endemic area in the west of Iran. Int J Infect Dis 2007; 11:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/22\">",
"      Colmenero JD, Ruiz-Mesa JD, Plata A, et al. Clinical findings, therapeutic approach, and outcome of brucellar vertebral osteomyelitis. Clin Infect Dis 2008; 46:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/23\">",
"      Mousa AM, Bahar RH, Araj GF, et al. Neurological complications of brucella spondylitis. Acta Neurol Scand 1990; 81:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/24\">",
"      Solera J, Lozano E, Mart&iacute;nez-Alfaro E, et al. Brucellar spondylitis: review of 35 cases and literature survey. Clin Infect Dis 1999; 29:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/25\">",
"      Bosilkovski M, Krteva L, Dimzova M, Kondova I. Brucellosis in 418 patients from the Balkan Peninsula: exposure-related differences in clinical manifestations, laboratory test results, and therapy outcome. Int J Infect Dis 2007; 11:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/26\">",
"      Pappas G, Bosilkovski M, Akritidis N, et al. Brucellosis and the respiratory system. Clin Infect Dis 2003; 37:e95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/27\">",
"      Mantur BG, Biradar MS, Bidri RC, et al. Protean clinical manifestations and diagnostic challenges of human brucellosis in adults: 16 years' experience in an endemic area. J Med Microbiol 2006; 55:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/28\">",
"      Rolando I, Olarte L, Vilchez G, et al. Ocular manifestations associated with brucellosis: a 26-year experience in Peru. Clin Infect Dis 2008; 46:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/29\">",
"      Ariza J, Servitje O, Pallar&eacute;s R, et al. Characteristic cutaneous lesions in patients with brucellosis. Arch Dermatol 1989; 125:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/30\">",
"      Ariza J, Bosilkovski M, Cascio A, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med 2007; 4:e317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/31\">",
"      Ariza J, Corredoira J, Pallares R, et al. Characteristics of and risk factors for relapse of brucellosis in humans. Clin Infect Dis 1995; 20:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/32\">",
"      Roushan MR, Gangi SM, Ahmadi SA. Comparison of the efficacy of two months of treatment with co-trimoxazole plus doxycycline vs. co-trimoxazole plus rifampin in brucellosis. Swiss Med Wkly 2004; 134:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/33\">",
"      Solera J, Mart&iacute;nez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs 1997; 53:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/34\">",
"      Solera J, Mart&iacute;nez-Alfaro E, Espinosa A, et al. Multivariate model for predicting relapse in human brucellosis. J Infect 1998; 36:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/35\">",
"      SPINK WW. What is chronic brucellosis? Ann Intern Med 1951; 35:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/36\">",
"      Al Dahouk S, Tomaso H, N&ouml;ckler K, et al. Laboratory-based diagnosis of brucellosis--a review of the literature. Part II: serological tests for brucellosis. Clin Lab 2003; 49:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/37\">",
"      Bosilkovski M, Katerina S, Zaklina S, Ivan V. The role of Brucellacapt test for follow-up patients with brucellosis. Comp Immunol Microbiol Infect Dis 2010; 33:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/38\">",
"      Mantec&oacute;n Mde L, Guti&eacute;rrez MP, Zarzosa Mdel P, et al. Influence of brucellosis history on serological diagnosis and evolution of patients with acute brucellosis. J Infect 2008; 57:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/39\">",
"      al-Eissa YA, Assuhaimi SA, al-Fawaz IM, et al. Pancytopenia in children with brucellosis: clinical manifestations and bone marrow findings. Acta Haematol 1993; 89:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/40\">",
"      Karakukcu M, Patiroglu T, Ozdemir MA, et al. Pancytopenia, a rare hematologic manifestation of brucellosis in children. J Pediatr Hematol Oncol 2004; 26:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/41\">",
"      al Deeb SM, Yaqub BA, Sharif HS, Phadke JG. Neurobrucellosis: clinical characteristics, diagnosis, and outcome. Neurology 1989; 39:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/42\">",
"      L&oacute;pez-Cort&eacute;s LF, Cruz-Ruiz M, G&oacute;mez-Mateos J, et al. Adenosine deaminase activity in the CSF of patients with aseptic meningitis: utility in the diagnosis of tuberculous meningitis or neurobrucellosis. Clin Infect Dis 1995; 20:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/43\">",
"      Araj GF, Lulu AR, Mustafa MY, Khateeb MI. Evaluation of ELISA in the diagnosis of acute and chronic brucellosis in human beings. J Hyg (Lond) 1986; 97:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/44\">",
"      Araj GF. Human brucellosis: a classical infectious disease with persistent diagnostic challenges. Clin Lab Sci 1999; 12:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/45\">",
"      Mantur BG, Mangalgi SS. Evaluation of conventional castaneda and lysis centrifugation blood culture techniques for diagnosis of human brucellosis. J Clin Microbiol 2004; 42:4327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/46\">",
"      Kolman S, Maayan MC, Gotesman G, et al. Comparison of the Bactec and lysis concentration methods for recovery of Brucella species from clinical specimens. Eur J Clin Microbiol Infect Dis 1991; 10:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/47\">",
"      Yagupsky P, Peled N, Press J, et al. Comparison of BACTEC 9240 Peds Plus medium and isolator 1.5 microbial tube for detection of Brucella melitensis from blood cultures. J Clin Microbiol 1997; 35:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/48\">",
"      Gotuzzo E, Carrillo C, Guerra J, Llosa L. An evaluation of diagnostic methods for brucellosis--the value of bone marrow culture. J Infect Dis 1986; 153:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/49\">",
"      Gazapo E, Gonzalez Lahoz J, Subiza JL, et al. Changes in IgM and IgG antibody concentrations in brucellosis over time: importance for diagnosis and follow-up. J Infect Dis 1989; 159:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/50\">",
"      Mert A, Ozaras R, Tabak F, et al. The sensitivity and specificity of Brucella agglutination tests. Diagn Microbiol Infect Dis 2003; 46:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/51\">",
"      Godfroid J, Cloeckaert A, Liautard JP, et al. From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis. Vet Res 2005; 36:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/52\">",
"      Young EJ. Serologic diagnosis of human brucellosis: analysis of 214 cases by agglutination tests and review of the literature. Rev Infect Dis 1991; 13:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/53\">",
"      Serra J, Vi&ntilde;as M. Laboratory diagnosis of brucellosis in a rural endemic area in northeastern Spain. Int Microbiol 2004; 7:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/54\">",
"      Memish ZA, Almuneef M, Mah MW, et al. Comparison of the Brucella Standard Agglutination Test with the ELISA IgG and IgM in patients with Brucella bacteremia. Diagn Microbiol Infect Dis 2002; 44:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/55\">",
"      Baldi PC, Giambartolomei GH, Wallach JC, et al. Limited diagnostic usefulness of antibodies to cytoplasmic proteins of Brucella in early-treated human brucellosis. Scand J Infect Dis 2001; 33:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/56\">",
"      Young EJ. Human brucellosis. Rev Infect Dis 1983; 5:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/57\">",
"      Gad El-Rab MO, Kambal AM. Evaluation of a Brucella enzyme immunoassay test (ELISA) in comparison with bacteriological culture and agglutination. J Infect 1998; 36:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/58\">",
"      ZINNEMAN HH, GLENCHUR H, HALL WH. The nature of blocking antibodies in human brucellosis. J Immunol 1959; 83:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/59\">",
"      Wilkinson PC. Immunoglobulin patterns of antibodies against Brucella in man and animals. J Immunol 1966; 96:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/60\">",
"      Morata P, Queipo-Ortu&ntilde;o MI, Reguera JM, et al. Development and evaluation of a PCR-enzyme-linked immunosorbent assay for diagnosis of human brucellosis. J Clin Microbiol 2003; 41:144.",
"     </a>",
"    </li>",
"    <li>",
"     Lindquist, D, Chu, MC, Probert, WWS. Francisella and Brucella. In: Manual of Clinical Microbiology (Ninth edition), Murray PR, Baron EJO, Jorgensen JH, Landry ML, Pfaller MA (Eds), ASM Press, Washington DC 2007. p.824.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/62\">",
"      Gee JE, De BK, Levett PN, et al. Use of 16S rRNA gene sequencing for rapid confirmatory identification of Brucella isolates. J Clin Microbiol 2004; 42:3649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/63\">",
"      Khateeb MI, Araj GF, Majeed SA, Lulu AR. Brucella arthritis: a study of 96 cases in Kuwait. Ann Rheum Dis 1990; 49:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/64\">",
"      Sommers H M. The microbiology laboratory in the diagnosis of infectious arthritis. Clin Rhemn Dis 1978; 4:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/65\">",
"      Goldenberg DL, Reed JI. Bacterial arthritis. N Engl J Med 1985; 312:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/66\">",
"      Julkunen, H. Reactive arthritis. Bull Rheum Dis 1978-1979; 29:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/67\">",
"      Andonopoulos AP, Asimakopoulos G, Anastasiou E, Bassaris HP. Brucella arthritis. Scand J Rheumatol 1986; 15:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/68\">",
"      Ariza J, Pigrau C, Ca&ntilde;as C, et al. Current understanding and management of chronic hepatosplenic suppurative brucellosis. Clin Infect Dis 2001; 32:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/69\">",
"      Pourbagher A, Pourbagher MA, Savas L, et al. Epidemiologic, clinical, and imaging findings in brucellosis patients with osteoarticular involvement. AJR Am J Roentgenol 2006; 187:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/70\">",
"      Solera J. Treatment of human brucellosis. J Med Liban 2000; 48:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/71\">",
"      Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev 2012; 10:CD007179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/72\">",
"      Pappas G, Papadimitriou P, Christou L, Akritidis N. Future trends in human brucellosis treatment. Expert Opin Investig Drugs 2006; 15:1141.",
"     </a>",
"    </li>",
"    <li>",
"     Joint Food and Agriculture Organization (FAO), World Health Organization (WHO). FAO-WHO expert committee on brucellosis (Sixth report). WHO technical report series, no 740. Geneva: World Health Organization; 1986: p. 56-7.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/74\">",
"      Hasanjani Roushan MR, Mohraz M, Hajiahmadi M, et al. Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans. Clin Infect Dis 2006; 42:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/75\">",
"      Ariza J, Gudiol F, Pallares R, et al. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. Ann Intern Med 1992; 117:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/76\">",
"      Solera J, Rodr&iacute;guez-Zapata M, Geijo P, et al. Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas. Antimicrob Agents Chemother 1995; 39:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/77\">",
"      Solera J, Mart&iacute;nez-Alfaro E, S&aacute;ez L. [Meta-analysis of the efficacy of the combination of +rifampicin and doxycycline in the treatment of human brucellosis]. Med Clin (Barc) 1994; 102:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/78\">",
"      Skalsky K, Yahav D, Bishara J, et al. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ 2008; 336:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/79\">",
"      Al-Tawfiq JA. Therapeutic options for human brucellosis. Expert Rev Anti Infect Ther 2008; 6:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/80\">",
"      Falagas ME, Bliziotis IA. Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies. Antimicrob Agents Chemother 2006; 50:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/81\">",
"      Akova M, Uzun O, Akalin HE, et al. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993; 37:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/82\">",
"      Karabay O, Sencan I, Kayas D, Sahin I. Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTN11871179]. BMC Infect Dis 2004; 4:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/83\">",
"      Mousa AR, Elhag KM, Khogali M, Marafie AA. The nature of human brucellosis in Kuwait: study of 379 cases. Rev Infect Dis 1988; 10:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/84\">",
"      Ranjbar M, Keramat F, Mamani M, et al. Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis. Int J Infect Dis 2007; 11:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/85\">",
"      El Miedany YM, El Gaafary M, Baddour M, Ahmed I. Human brucellosis: do we need to revise our therapeutic policy? J Rheumatol 2003; 30:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/86\">",
"      Mantur BG, Akki AS, Mangalgi SS, et al. Childhood brucellosis--a microbiological, epidemiological and clinical study. J Trop Pediatr 2004; 50:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/87\">",
"      al-Eissa YA, Kambal AM, al-Nasser MN, et al. Childhood brucellosis: a study of 102 cases. Pediatr Infect Dis J 1990; 9:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/88\">",
"      Alp E, Doganay M. Current therapeutic strategy in spinal brucellosis. Int J Infect Dis 2008; 12:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/89\">",
"      Alp E, Koc RK, Durak AC, et al. Doxycycline plus streptomycin versus ciprofloxacin plus rifampicin in spinal brucellosis [ISRCTN31053647]. BMC Infect Dis 2006; 6:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/90\">",
"      Pappas G, Seitaridis S, Akritidis N, Tsianos E. Treatment of brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen. Int J Antimicrob Agents 2004; 24:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/91\">",
"      Pappas G, Akritidis N, Christou L. Treatment of neurobrucellosis: what is known and what remains to be answered. Expert Rev Anti Infect Ther 2007; 5:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/92\">",
"      Gul HC, Erdem H, Gorenek L, et al. Management of neurobrucellosis: an assessment of 11 cases. Intern Med 2008; 47:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/93\">",
"      Erdem H, Ulu-Kilic A, Kilic S, et al. Efficacy and tolerability of antibiotic combinations in neurobrucellosis: results of the Istanbul study. Antimicrob Agents Chemother 2012; 56:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/94\">",
"      McLean DR, Russell N, Khan MY. Neurobrucellosis: clinical and therapeutic features. Clin Infect Dis 1992; 15:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/95\">",
"      Lulu AR, Araj GF, Khateeb MI, et al. Human brucellosis in Kuwait: a prospective study of 400 cases. Q J Med 1988; 66:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/96\">",
"      Mert A, Kocak F, Ozaras R, et al. The role of antibiotic treatment alone for the management of Brucella endocarditis in adults: a case report and literature review. Ann Thorac Cardiovasc Surg 2002; 8:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/97\">",
"      Koruk ST, Erdem H, Koruk I, et al. Management of Brucella endocarditis: results of the Gulhane study. Int J Antimicrob Agents 2012; 40:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/98\">",
"      Montejo JM, Alberola I, Glez-Zarate P, et al. Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis. Clin Infect Dis 1993; 16:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/99\">",
"      Tanir G, Tufekci SB, Tuygun N. Presentation, complications, and treatment outcome of brucellosis in Turkish children. Pediatr Int 2009; 51:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/100\">",
"      El-Amin EO, George L, Kutty NK, et al. Brucellosis in children of Dhofar Region, Oman. Saudi Med J 2001; 22:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/101\">",
"      Issa H, Jamal M. Brucellosis in children in south Jordan. East Mediterr Health J 1999; 5:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/102\">",
"      Khuri-Bulos NA, Daoud AH, Azab SM. Treatment of childhood brucellosis: results of a prospective trial on 113 children. Pediatr Infect Dis J 1993; 12:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/103\">",
"      Lubani MM, Dudin KI, Sharda DC, et al. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr Infect Dis J 1989; 8:75.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Brucellosis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/105\">",
"      Roushan MR, Mohraz M, Janmohammadi N, Hajiahmadi M. Efficacy of cotrimoxazole and rifampin for 6 or 8 weeks of therapy in childhood brucellosis. Pediatr Infect Dis J 2006; 25:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/106\">",
"      Gottesman G, Vanunu D, Maayan MC, et al. Childhood brucellosis in Israel. Pediatr Infect Dis J 1996; 15:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/107\">",
"      S&aacute;nchez-Tamayo T, Colmenero JD, Mart&iacute;nez-Cort&eacute;s F, et al. Failure of short-term antimicrobial therapy in childhood brucellosis. Pediatr Infect Dis J 1997; 16:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/108\">",
"      Lubani MM, Dudin KI, Araj GF, et al. Neurobrucellosis in children. Pediatr Infect Dis J 1989; 8:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/109\">",
"      Habeeb YK, Al-Najdi AK, Sadek SA, Al-Onaizi E. Paediatric neurobrucellosis: case report and literature review. J Infect 1998; 37:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/110\">",
"      Omar FZ, Zuberi S, Minns RA. Neurobrucellosis in childhood: six new cases and a review of the literature. Dev Med Child Neurol 1997; 39:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/111\">",
"      Centers for Disease Control and Prevention (CDC). Laboratory-acquired brucellosis--Indiana and Minnesota, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:39.",
"     </a>",
"    </li>",
"    <li>",
"     Wright SG. Brucellosis. In: Hunter&rsquo;s Tropical Medicine and Emerging Infectious Diseases, 8th ed, Strickland GT (Ed), W.B. Saunders Company, Philadelphia 2000. p.416.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/113\">",
"      Corbel MJ. Brucellosis: an overview. Emerg Infect Dis 1997; 3:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/114\">",
"      Cassataro J, Pasquevich KA, Estein SM, et al. A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine 2007; 25:5958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/43/16058/abstract/115\">",
"      Commander NJ, Spencer SA, Wren BW, MacMillan AP. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Vaccine 2007; 25:43.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3140 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-D8E5382BBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16058=[""].join("\n");
var outline_f15_43_16058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2043730\">",
"      Acute brucellosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H243133425\">",
"      - Localized infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2045094\">",
"      Relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H243133450\">",
"      Chronic brucellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Serologic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Molecular tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22055922\">",
"      Synovial fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22055929\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2045332\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Major regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Alternative agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2045356\">",
"      Focal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H243133482\">",
"      - Spondylitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1706658799\">",
"      - Neurobrucellosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1706658805\">",
"      - Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1706658861\">",
"      Relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2045448\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22057110\">",
"      Post exposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2045253\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3140\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3140|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/13/14546\" title=\"diagnostic image 1\">",
"      Snowflake calficification on CT in brucellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3140|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/33/21021\" title=\"table 1\">",
"      Clinical manifestations - Brucellosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/1/19485\" title=\"table 2\">",
"      Laboratory findings - Brucellosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/49/41756\" title=\"table 3\">",
"      Brucella postexposure recs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33751?source=related_link\">",
"      Microbiology, epidemiology, and pathogenesis of Brucella",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_43_16059="Phases lung development";
var content_f15_43_16059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Phases of lung development",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gestational age, weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stage of lung development",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0 to 5",
"       </td>",
"       <td>",
"        Embryonic",
"       </td>",
"       <td>",
"        Lung bud arises",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 to 17",
"       </td>",
"       <td>",
"        Pseudoglandular",
"       </td>",
"       <td>",
"        Nonrespiratory bronchi and bronchioles develop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17 to 24",
"       </td>",
"       <td>",
"        Canalicular",
"       </td>",
"       <td>",
"        First gas exchanging acini and pulmonary capillaries are forming",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25 to 37",
"       </td>",
"       <td>",
"        Terminal sac",
"       </td>",
"       <td>",
"        Subsaccules and alveoli develop with extensive capillary invasion and expansion of the alveolar-blood barrier surface area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38 to age 3 years",
"       </td>",
"       <td>",
"        Alveolar",
"       </td>",
"       <td>",
"        Subsaccules become alveoli",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16059=[""].join("\n");
var outline_f15_43_16059=null;
var title_f15_43_16060="Hypertensive emergencies";
var content_f15_43_16060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hypertensive emergencies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Accelerated-malignant hypertension with papilloedema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Cerebrovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypertensive encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Atherothrombotic brain infarction with severe hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intracerebral hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Subarachnoid hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Cardiac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute aortic dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute left ventricular failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute or impending myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        After coronary bypass surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Renal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Renal crises from collagen vascular diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Severe hypertension after kidney transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Excessive circulating catecholamines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pheochromocytoma crisis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Food or drug interactions with monoamine-oxidase inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sympathomimetic drug use (cocaine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rebound hypertension after sudden cessation of antihypertensive drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eclampsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Surgical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Severe hypertension in patients requiring immediate surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Postoperative hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Postoperative bleeding from vascular suture lines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe body burns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe epistaxis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16060=[""].join("\n");
var outline_f15_43_16060=null;
var title_f15_43_16061="Levels TNF and NYHA class";
var content_f15_43_16061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Levels of tumor necrosis factor alpha correlate with NYHA functional",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 316px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Circulating levels of tumor necrosis factor alpha (TNFa) are significantly higher in patients with heart failure compared to normals (1.95 versus 0.75 pg/mL). Levels were progressively elevated in relationship to decreasing functional status of the patient; levels were highest in those with NYHA class III compared to those with NYHA class I heart failure or controls.",
"    <div class=\"footnotes\">",
"     * p = 0.001.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Torre-Amione G, Kapadia S, Benedict C, et al. J Am Coll Cardiol 1996; 27:1201.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16061=[""].join("\n");
var outline_f15_43_16061=null;
var title_f15_43_16062="Follicle number and age";
var content_f15_43_16062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 586px\">",
"   <div class=\"ttl\">",
"    Declining follicle number with age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 566px; height: 358px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A comparison of the relationship between age and primordial follicle number in Block's study of 44 girls and women aged 7 to 44 years with that of Gougeon's study of women aged 45 to 55 years. Follicle depletion appears to accelerate in the decade preceding menopause.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <ol>",
"      <li>",
"       Block E. Quantitative morphological investigations of the follicular system in women; variations at different ages.&nbsp;Acta Anat 1952; 14:108",
"      </li>",
"      <li>",
"       Gougeon A. Caract&egrave;res qualitatifs et quantitatifs de la population folliculaire dans l&oacute;vaire humain adulte.&nbsp;Contr Fert Sex 1984; 12:527.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16062=[""].join("\n");
var outline_f15_43_16062=null;
var title_f15_43_16063="CFTR gene and CF";
var content_f15_43_16063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    CFTR gene",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 337px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the CFTR gene and its encoded polypeptide. &Delta;F508 refers to the site of the&nbsp;most common&nbsp;mutation&nbsp;causing cystic fibrosis.",
"    <div class=\"footnotes\">",
"     CFTR: cystic fibrosis transmembrane conductance regulator",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Welsh, MJ, Tsui, L-C, Boat, T, Beaudet, AL. Cystic fibrosis. In: The Metabolic and Molecular Basis of Inherited Disease, Scriver, CR, Beaudet, AL, Sly, WS, et al (Eds), McGraw-Hill, New York, 1995, p. 3801.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_43_16063=[""].join("\n");
var outline_f15_43_16063=null;
